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From the Editor’s Desk
Dear Readers
I hope all our readers are in good health and
managing these uncertain times as best they can.
The rapid spread of the Coronavirus Disease 2019
(COVID-19) poses unprecedented challenges in
Pakistan and across the globe. To serve the health care
community at such a critical time, the LABRAD team
has created a special issue pertaining to this global
pandemic. One of the biggest lengthiest issue of its
time, LABRAD offers a great variety of articles all
related to COVID-19 to keep you informed on how
to address this ever-evolving pandemic using the
best available information. This issue also includes
an interview of the Chair of the Department of
Pathology and Laboratory Medicine and how she led
the department in these challenging times. As the
current pandemic problem extends to all parts of the
country, we anticipate that this issue will be helpful to
all our readers from across the country in providing
high-quality, safe, effective and optimal care to their
patients.
The day we decided to have a special issue of
LABRAD on COVID-19 my whole newsletter
team sprang into action. Whether, it was sending
call for articles, gathering pictures (don’t forget to
check the Polaroid section of LABRAD), taking
appreciative inquiries (Best of the Past) reactions, or

writing. Every single person in my team was ready to
contribute and give it their best. The newsletter team
remain connected throughout these past few weeks
via WhatsApp and emails and compiled this issue
completely remotely. The information in the current
newsletter was conceived and compiled by staff,
residents and faculty of the Departments of Pathology
and Laboratory Medicine and Radiology.
Headed into the summer, there are umpteen questions
we don’t have answers to. In this anxiety producing
environment of pandemic, I would encourage all
of you to stay positive. Keep on looking over the
horizon and come up with innovative ideas to fight
this COVID-19 pandemic. Stay connected to each
other and keep discussing your ideas. The wealth of
knowledge that can be gained from the experience of
others should never be underestimated. Transmission
of ideas should be sticky and as aggressive as
COVID-19!
We truly are in this together, and that is precisely how
we will get through it to a better future. Please take
care, and stay safe.

Dr Lena Jafri
Clinical Chemistry

Pathophysiology of Lung Injury in Context
with Novel Coronavirus 2019
Dr Qurratulain Chundriger and Dr Nasir Ud Din
Section of Histopathology

Coronaviruses are large enveloped RNA viruses.
The human coronaviruses cause lower respiratory
infections apart from being the causative agents
of common cold and gastroenteritis in infants.
COVID-19 or SARS-Cov-2, a type of beta-COV, is
a novel strain of the Human Coronaviruses that was
first identified in the latter part of 2019 as a cluster

of pneumonia cases. In January 2020, the Chinese
authorities identified a novel type of coronavirus,
which was later named severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2). Until
recently, only two beta coronaviruses — severe acute
respiratory syndrome coronavirus (SARS-CoV)
and Middle East respiratory syndrome coronavirus
3
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(MERS-CoV) — have caused significant human
morbidity and mortality.

those who succumbed, exhibited severe ground glass
opacities and white lung on CT scans.

Pathophysiology: The COVID-19 has four major
structural proteins: the spike surface glycoprotein,
small envelope protein, matrix protein, and
nucleocapsid protein. Coronaviruses exhibit a tropism
for the epithelial membranes of the respiratory
tract in particular. When a person is infected by
COVID-19, the petal shaped glycoprotein spikes on
the surface of the viral capsid attach to the epithelial
cell via receptor binding domains of the Angiotensin
Converting Enzyme II (ACEII) which is most
abundant in type II pneumocytes. It is also found
in other organs like gastrointestinal tract, kidney,
lymph nodes, thymus, bone marrow, spleen and brain.
The RNA of the virus is then endocytosed into the
cytoplasm of the infected cell, where it first creates
the viral RNA polymerase and then starts replicating.
Multiple newly formed virions are then shed from the
cell and infect other nearby cells.

Microscopic findings: Only a handful of studies
have been published so far which have described the
histopathological findings of patients with severe
disease and those who died of COVID-19. The
clinical picture is that of pneumonia and ARDS. The
pathological findings are of Diffuse Alveolar Damage
(DAD) which is the most common histopathologic
correlate of ARDS. DAD shows an early exudative
phase and a late organizing phase. In the exudative
phase, there are rounded organizing plugs of exudate
in the terminal bronchioles and protein-rich edema
in the alveolar space, with fibrin-rich eosinophilic
hyaline membranes along the surface of the alveolar
septa (Figure 1).This results in inability of the lungs
to perform the vital function of gaseous exchange
through the damaged and so-called blocked
pulmonary alveolar spaces. There can be proliferation
of type II pneumocytes, accompanied by reactive
nuclear changes in these cells, i.e. enlargement of the
nuclei and mild atypia. The interstitium shows edema
with scant number of inflammatory cells including
lymphocytes, plasma cells and/or neutrophils,
depending on the underlying etiology. The term
“diffuse” refers to complete involvement of the
pulmonary lobule and not necessarily the entire lung
tissue. One study has also described multinucleated
syncytial cells with atypical enlarged pneumocytes
characterized by large nuclei, amphophilic granular
cytoplasm, and prominent nucleoli were identified in
the intra-alveolar spaces, showing viral cytopathiclike changes. Viral inclusions were not identified.
Large areas of intra-alveolar hemorrhages and intraalveolar fibrin cluster formation were observed in
another study. All these changes have been described
in autopsy findings of COVID-19 decedents, who
had increased weights of lungs due to edema or
consolidation and adhesions grossly. The organizing
phase may show interstitial thickening and fibrinoid
necrosis of small vessels along with alveolar edema
and pleural fibrosis with adhesions. Some or may
be most of the cases under the microscope show a
variable mixture of areas of both exudative as well as
organizing phases. Findings representing the fibrotic
phase (e.g. dense collagenous fibrosis, architectural
remodeling) are not reported so far.

Clinical presentation: In 80 percent of cases,
immune system fights back resulting in mild to
moderate symptoms of cough, chest pain, fever and
some degrees of shortness of breath. Upto 14 percent
of COVID-19 infected individuals develop severe
disease, most of these patients have a pre-existing
condition that makes them highly vulnerable. These
may be geriatric patients, immunocompromised
individuals, chronic smokers, those with underlying
pulmonary or cardiac dysfunction and diabetics to
list a few. These patients present with hypoxemia or
multi organ dysfunction and may require mechanical
ventilation.
ARDS and Radiological findings: About five percent
cases develop Acute Respiratory Distress Syndrome
or ARDS, which shows characteristic radiological
findings on standard X-Rays and CT scans. According
to the studies published so far, the imaging features
of COVID-19 pneumonia are diverse, ranging from
normal appearance to diffuse changes in the lungs. In
addition, different radiological patterns are observed
at different times throughout the disease course. One
study showed slight predilection for the right lower
lobe. The most common findings were ground glass
opacities, variable degrees of septal thickening,
nodules, cystic changes, pleural effusions and
thickenings. Of these, patients with severe disease and
4

Figure 1. Lung tissue showing formation of hyaline
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membranes which line the alveolar spaces with loss of
alveolar pneumocytes. In addition, there are changes
of pneumonia i.e. interstitial inflammation and
widening, along with congested vessels and areas of
hemorrhage.
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No significant histopathological abnormalities were
reported in other tissues like the heart and liver in
patients who died of COVID-19. These organs showed
changes pertaining to either an underlying condition,
like liver cirrhosis and or changes related to prolonged
hospitalization and drug related injury, such as
microvesicular steatosis in hepatocyte lobules. Only
few autopsy studies and a couple of studies of core
biopsies from patients who recovered from COVID
related illness have been reported in the literature so
far, all of these from china and the western world.
In Pakistan, we are way behind them as autopsies
are not routinely performed for non-medico legal
purposes and there is no trend of doing core biopsies
from patients with any degree of symptomatic
COVID-19 illness. As reports of atypical presentation
are continuously being made, this strain of the
coronavirus presents an entire horizon of clinical,
radiological and pathological features to be explored.

Imaging in COVID-19 Pandemic: Salient
Features
Dr Shaista Afzal
Radiology

The entire world is experiencing an outbreak caused
by the novel Corona virus that originated from
Wuhan, China in December 2019. The disease was
officially announced as a pandemic by World Health
Organization (WHO) on the 11th of March 2020. At
first, the disease appeared in a few clusters affecting
individuals with advanced age or co-morbidities;
however, it is now widespread. COVID-19 can cause
severe pneumonia and fatal respiratory disease
especially acute respiratory distress syndrome
(ARDS). The predominant clinical features of
COVID-19 infection are fever, fatigue, malaise,
dry cough and other respiratory symptoms. Early
detection and diagnosis of this highly contagious
disease is vital to control the outbreak; hence, it is
important to separate suspected cases and contacts.
In the present times the diagnosis is mainly based on
the patient’s epidemiological history, clinical features,
laboratory tests especially the reverse transcriptase
polymerase chain reaction (RT-PCR) for COVID-19

and chest imaging features. The radiologist plays an
important role in the early diagnosis and identification
of a suspected COVID-19 individual which can be of
great help not only to the patient but also for public
health surveillance and response authorities. This
short communication briefly introduces the chest
X-ray and CT imaging features of this novel corona
virus infection with focus on the value of imaging in
its diagnostic workup.
Chest X Ray
Chest x-ray is not routinely performed in the clinical
workup of a suspected COVID-19 patient because
it is not sensitive in the early stage of the disease.
However, with the progression of disease beyond the
early stage, the chest x-ray may show multiple patchy
opacities, predominantly at peripheral and bases, and
in bilateral lung fields. (Figure 1 & 4a) With further
severity of disease, there develops confluence of
5
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opacities that results in “whited out lung”. Pleural
effusion has also been reported in severe cases. The
findings have been reported to develop over the time
course of the disease.
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comprising of pleural thickening and pleural effusion
have also been reported, with the former feature being
more prevalent. Poor prognosis is reported in patients
who develop pleural effusion. Recent literature
further reports the presence of lymphadenopathy and
pericardial effusion in critical COVID-19 patients.

Figure 1: X ray chest, AP sitting projection, shows multiple
inhomogeneous opacities in the periphery of bilateral lung fields

CT (Computed Tomography) Chest
For COVID-19 diagnosis, RT-PCR is regarded as the
reference standard. However, as reported in recent
studies, CT chest has shown a sensitivity of 98%,
especially in patients with false negative RT-PCR.
CT chest also plays an important role in the evaluation
of therapeutic efficacy and monitoring of disease
progression. The common imaging features of
COVID-19 on CT chest are ground glass opacities
which are multiple, patchy, bilaterally distributed
mostly along the bronchovascular bundle, with or
without consolidation, and predominantly in the
posterior and peripheral lungs. (Figure 2 , 3 &4b)
Other features include reversed halo sign, crazy
paving pattern and airway changes. Pleural changes

Figure 2: Unenhanced CT chest examination: Bilateral, basal, ground
glass opacities with some crazy paving. The disease is predominantly
peripheral in distribution with perihilar sparing.
Classic imaging features of COVID-19 infection are seen

6

Figure 3: Multiplanar reformatted coronal image, with HRCT protocol.
There is evidence of groundglass appearance and patchy areas of
consolidation in the periphery of bilateral lung fields, predominantly on
the right side in keeping with COVID-19.

Figure 4a: X-ray chest AP sitting view.
Patchy areas of consolidation in bilateral lung fields
predominantly involving subpleural location
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Conclusion

Figure 4b: HRCT examination of the above patient (4a), Multifocal,
patchy areas of dense groundglass haze as well as scattered
consolidations identified in both lung fields with predominant subpleural
involvement, appearances are highly suggestive of COVID pneumonia.

In the present situation, imaging of COVID-19
patients especially with CT Chest is very valuable
because it shows characteristic imaging features
of COVID-19 infection. This shall enable
frontline physicians to diagnose patients even
when laboratory results are false negative. An
early diagnosis with the help of imaging may
thus facilitate containment of the disease and
overcoming of the outbreak.

Qualitative Real-Time RT-PCR For Detection
of SARS-Cov-2 RNA
Dr Kiran Iqbal and Dr Najia Ghanchi
Molecular Pathology

The global outbreak of novel coronavirus, SARSCoV-2 (COVID-19), caused over 100,000 deaths
and more than 1 500,000 infected sending several
countries to lock down. COVID-19 is caused by
SARS-CoV-2 which belongs to a family of beta
corona viruses. It was first discovered in the Wuhan, a
city in the Hubei Province of China in 2019. It belongs
to the same subgenus as that of the severe acute
respiratory syndrome (SARS) virus but to a different
clade. SARS-CoV-2 virus appears spherical in shape.
It has spike like proteins protruding from the surface
of the virus particle. Recent work shows that SARSCoV2 attaches to human cell receptor angiotensinconverting enzyme two (ACE2) using its spike like
proteins which than undergoes a structural change
allowing the viral membrane to fuse with the human
cell membrane. The viral genes then enter
into the host producing more viruses.
Transmission is through droplets and the incubation
period is 14 days following exposure. Patients who
are affected with SARS-CoV2 presents with fever
and acute respiratory symptoms including cough
and dyspnea. In case of severe manifestation,
patient presents with pneumonia having bilateral
infiltrates on chest X-ray. Patients with compromised
immune responses including old age or underlying
comorbidities are reported to develop more severe

Figure 1: Structure and genome organization of SARS-CoV-2.
A) structure of SARS-CoV 2 viron.
B) Relative positions of amplicon targets on SARS-CoV genome.
N: nucleocapsid, ORF: open reading frame.

disease. The global fatality rate is reported to
be around two percent. People who are at risk
of getting COVID 19 are the ones who live in
or have travelled to the areas where community
transmission has been reported or the ones who
have had a close contact with confirmed cases.
Patients suspected of COVID-19 should undergo
testing for SARS-CoV2 along with testing for other
possible respiratory pathogens. Appropriate sample
including upper respiratory specimen (oropharyngeal
and nasopharyngeal swab) or lower respiratory
specimen (sputum) is sent to the lab in a viral/
universal transport medium. Nucleic acid extraction
7
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is performed and the sample is subjected to realtime reverse transcription polymerase chain reaction
(rRT-PCR) for the detection of SARS-CoV2 RNA.
The viral genes targeted for testing include the N, E,
S and RdRP genes. E gene is targeted as a first line
screening assay for pan-Sarbecovirus detection. For
confirmation RdRp and ORF1/a non-structural gene
are being tested. PCR detects SARS-CoV-2 RNA that
are detectable in nasopharyngeal and Oropharyngeal
swab samples during infection. Positive results are
indicative of SARS-CoV-2 RNA detection, but may
not represent the presence of transmissible virus.
Negative results do not preclude SARS-CoV-2
infection and should not be used as the sole basis for
patient management decisions and must be correlated
with clinical, patient history, and epidemiological
information.

VOL 46, ISSUE 2
Patients tested positive should be isolated and
provided with supportive treatment. Antiviral
treatment for COVID-19 is under investigation.
Patients with mild infections can be managed at home
provided they stay at home in a separate room from
other people and animals in the house. They should
wear a facemask when with someone or when visiting
health care settings. No vaccine or specific treatment
for COVID-19 is available and care is supportive
Many aspects of the virus and disease are still not
understood. A better understanding will be needed to
provide improved guidance.

Coagulopathy and Anticoagulants in COVID-19
Dr Kanta Devi
Hematology Transfusion Medicine

The 2019 novel coronavirus (COVID-19) presents
with a variety of phenotypes that range from
asymptomatic to profound, rapid multiple organ
dysfunction syndrome (MODS) and death.
Proposed mechanisms for MODS in COVID-19 are
multifactorial but include a hypercoagulable state
with micro and macro-circulatory thrombosis.
Recent observations and autopsy findings suggest
that respiratory failure in COVID-19 is not driven
by the development of the acute respiratory distress
syndrome (ARDS) alone, but that
(microvascular) thrombotic processes
may play a role as well. This may
have important consequences for the
diagnostic and therapeutic management
of these patients. There is a strong
association between D-dimer levels,
disease progression and chest CT features
suggesting venous thrombosis.
A strong predictor of mortality is
disseminated intravascular coagulation
(DIC). A significant increase in D-dimer
8

and prothrombin with a decrease in fibrinogen in
non-survivors at days 10-14 is also reported. This
highlights the importance of regular and continued
monitoring of these levels.
D-Dimer is a degradation product of cross-linked
fibrin and reflects blood clot formation and its
subsequent fibrinolysis. Testing uses an enzymelinked immunoabsorbent assay (ELISA) or microlatex
agglutination assay . D-dimer has a very high
sensitivity for thrombotic disease, but its specificity
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is poor. Elevated D-dimer (above 1 μg/mL) was a
strong and independent risk factor for death in this
population.

A

Diffuse Alveolar Damage

B

Microthrombi in Small
Pulmonary Arterioles

C

Pathology Findings
Microvascular thrombosis is hypothesized to
be involved in hypoxemic respiratory failure in
some patients with COVID-19. Autopsy studies
to date have been limited, with some suggesting
microvascular thrombosis and others showing
pulmonary hemorrhage. Whether the coagulation
cascade is directly activated by the virus or whether
this is the result of local or systemic inflammation
is not completely understood. High plasma levels
of proinflammatory cytokines (interleukin-2,
interleukin-7, granulocyte colony-stimulating factor,
IP10, MCP1, MIP1A and tumor necrosis factor-α)
have been observed in COVID-19 patients admitted to
intensive care units. . While many pro-inflammatory
cytokines trigger the coagulation system, showed
that the increase in IL-6 was discrepant with
the elevations in D-dimer; IL-6 levels appeared
to increase only 13 days after disease onset,
whereas D-dimer levels were already 10-fold
increased by that time. This observation suggests
that the very high D-dimer levels observed in
COVID-19 patients are not only secondary to
systemic inflammation, but also reflect true
thrombotic disease, possibly induced by cellular
activation that is triggered by the virus.

Microthrombi in Small
Pulmonary Arterioles
Microthrombi in Small
Pulmonary Arterioles

D

cohort study (Tonghi hospital) of 449 consecutive
patients classified as having severe COVID-19
indicates that prophylactic doses of heparins might
be associated with improved survival (20 percent) in
patients with evidence of sepsis induced coagulopathy
(SIC)/DIC). Severe COVID-19 was defined as either
a respiratory rate ≥30/min, arterial oxygen saturation
≤93 percent at rest, or PaO2/FiO2 ≤300 mmHg.
Exclusion criteria included bleeding diathesis, hospital
stay <7 days and lack of information of coagulation
parameters and medications. Heparin was associated
with lower 28-day mortality.
American Society of Hematology recommends all
hospitalized patients with COVID-19 should receive
thromboprophylaxis with LMWH or fondaparinux
(suggested over unfractionated heparin to reduce
contact) unless the patient is judged to be at increased
risk of bleeding. In patients with a history of heparininduced thrombocytopenia (HIT) use fondaparinux.

l

Bottom Line: this report supports the concept of
hypercoagulative status, showing high frequency of
pulmonary microthrombosis

Role of Antithrombotic Therapy
Notably, a Chinese single-center retrospective
9
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Serum Procalcitonin - A Marker to
Differentiate Bacterial from Viral Infection
Dr Zaib-un-Nisa
Clinical Chemistry

Procalcitonin (PCT) is the peptide precursor of
calcitonin, a hormone that is synthesized by the
parafollicular C cells of the thyroid and involved
in calcium homeostasis. Procalcitonin arises from
endopeptidase-cleaved preprocalcitonin. It is also
produced by the neuroendocrine cells of the lung and
intestine and is released as an acute-phase reactant in
response to inflammatory stimuli, especially those of
bacterial origin. It is a biomarker that exhibit greater
specificity than other pro-inflammatory markers (eg,
cytokines) in identifying sepsis and can be used in the
diagnosis of bacterial infections.
PCT production is induced in response to microbial
toxins and to certain bacterial-induced cytokines,
particularly interleukin (IL)-1β, tumor-necrosis
factor (TNF)-α and IL-6, and is released in the
bloodstream where it can be measured Conversely,
PCT production is attenuated by certain cytokines
released in response to a viral infection, particularly
interferon-γ (IFN-γ). This selective cellular
mechanism makes PCT a useful diagnostic biomarker,
which is more specific for bacterial infections and
helps to distinguish bacterial infections from other
inflammatory reactions or viral infections. The raised
Procalcitonin level during inflammation is associated
with bacterial end toxin and inflammatory cytokines.
Increased levels of serum procalcitonin in response
to viral infections and noninfectious inflammatory
stimuli such as autoimmune disease and chronic
inflammatory processes are much less pronounced,
rarely exceeding 0.5 ng/mL. The reference cutoffs are
shown in Table 1.
Table 1: Interpretation of Procalcitonin Levels:
Test Name
Reference Cutoffs
< 0.5 ng/mL represents a low
risk of severe sepsis and/or
septic shock
Pro Calcitonin

Septic
shock

10ng/ml
Severe
sepsis

2ng/
ml

>0.5ng/ml

Antibiotic
strongly
encouraged

0.250.5ng/ml

Antibiotic
encouraged

0.10.25ng/ml

Antibiotic
discouraged

<0.1ng/
ml

Antibiotic
strongly
discouraged

sepsis

Local
infection

0.5ng/
ml PCT algorithm
for antibiotic
therapy

0.05ng/
ml
Serum PCT
level during
sepsis

Figure 1: Algorithm for use of PCT for antibiotic Therapy.
(Reference:Vijayan et al. Journal of Intensive Care (2017) 5:51; DOI
10.1186/s40560-017-0246-8)

Aid the preference and timing of the initiation
of antibiotic treatment (Procalcitonin Algorithm)

l

Conditions associated
•
•
•

Localized mild-to-moderate bacterial infection
Noninfectious systemic inflammatory response
Untreated end-stage renal failure

•
•

Bacterial sepsis
Severe noninfectious inflammatory stimuli (e.g., major burns,
severe trauma, acute multiorgan failure, major abdominal or
cardiothoracic surgery).
Medullary thyroid carcinoma (may exceed 10,000 ng/mL).

2.0 ng/mL represent a high risk of
severe sepsis and/or septic shock.
•

10

PCT levels intensify within two–four hours of
infection and the maximum level is reached by six–
eight hours and with continued infection or sepsis the
elevated level persists and decreases once infection is
controlled. Its half-life is about 20–24 hours. Its levels
persist as long as the inflammatory process continues
and the level correlate with the severity of sepsis. The
applications or indications of testing PCT include to:
l Aid in the diagnosis and risk stratification of
		 bacterial sepsis.
l Aid in distinguishing bacterial from viral
		 infections, including meningitis.
l Screen therapeutic response to antibacterial
		 therapy and reduce antibiotic exposure.

JUNE 2020
for improved antibiotic stewardship. The figure 1
shows the algorithm of PCT which can be utilized in
antibiotic therapy.
l
Aid in the diagnosis of systemic secondary
infection after surgery and in severe trauma, burns,
and multiorgan failure.

COVID-19 and Procalcitonin
The PCT is now considered an important parameter
for earlier identification of COVID-19 patients at
risk of developing bacterial co-infection. A report by

VOL 46, ISSUE 2
Guan W. et al. (NEJM Feb 2020) showing data from
different medical centers of China, including 1099
COVID-19 patients reported that their PCT levels
were low (<0.5 µg/L) in > 96 percent of cases with
low disease severity and absence of adverse outcome
(combined endpoint of ICU admission, invasive
ventilation, death). Another report by Zhou et al.
reported that COVID-19 patients may even present
with PCT levels <0.25µg/L or even below 0.1 µg/L
(Lancet Mar 2020). PCT testing on admission seems
to be a valuable additional piece of information to
aid in early risk assessment and rule-out of bacterial
coinfection in COVID-19 patients.

Role of C-Reactive Protein (CRP) in COVID-19
Ms Iffat Arman
Clinical Chemistry

COVID-19 is a viral disease, for which there is
currently no treatment. It is therefore necessary
to explore biomarkers to determine the extent
of lung lesions and disease severity. New
coronavirus pneumonia (COVID-19) is a health
emergency due to its high infectiousness and high
case fatality in critically ill patients. Clinical
monitoring and appropriate treatment strategies
were essential to improve case fatality. The
pathological and physiological processes and
diagnostic methods of COVID-19 are still in the
exploratory stage.
The CRP levels are used in the early diagnosis
of pneumonia and patients presenting with
severe pneumonia have high CRP levels.
Correlation between CRP levels, lung lesions,
and disease severity to provide reference for
clinical treatment. It was first discovered in a
patient with lobar pneumonia in 1930 by Tillet
& Francis. The CRP is a protein produced in
response to infection or inf lammation and it
is widely used in clinical tests to diagnose
and manage patients with sepsis. It is an acute
phase reactant whose synthesis in the liver is
up- regulated by Interleukin-6. Its response is
stronger in acutely ill patients and levels decrease
as patients recover. It should be used cautiously

in patients with sepsis, as it is also a marker of
inf lammation that also increases after surgery,
burns, myocardial infarctions, and rheumatic
diseases. A rapid decrease in CRP levels has
been reported to correlate with good response to
initial antimicrobial therapy in septic patients.
The plasma half-life of CRP is 19 hours. The
sensitivity and specificity of CRP as a marker for
bacterial infections are 68–92 percent and 40–67
percent, respectively.
Although CRP does not normally elevate
significantly in mild viral respiratory infections,
levels have shown to increase in severe cases,
such as in avian inf luenza H1N1 and H7N9,
and during SARS epidemics in 2003. A
similar significant increase of CRP has also
been reported in COVID-19 patients. One
possible explanation for this phenomenon is the
overproduction of inf lammatory cytokines that
take part in the defense against the pathogen, but
also cause more severe symptoms and damage
in lung alveoli and stimulate CRP production.
Therefore, CRP testing may be useful in the
initial evaluation of coronavirus patients. It
provides an important clinical evaluation index,
and levels can ref lect disease changes, especially
for patients who are not in critical condition.
11
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A Snapshot of the Biochemical Markers Used
in the Monitoring of COVID-19 Cases
Dr Sibtain Ahmed
Clinical Chemistry

Coronavirus disease 2019 (COVID-19), caused by
severe acute respiratory syndrome coronavirus Two
(SARS-CoV-2) has emerged as a life-threatening
global pandemic. The role of clinical laboratories
begins with the etiological diagnosis based on
real-time reverse transcription polymerase chain
reaction and extends beyond to disease surveillance,

monitoring disease severity, evaluating prognosis
and therapeutic drug monitoring via numerous
biochemical markers.
The table below summarizes the role of various
biochemical markers alongside their interpretation
and clinical significance in COVID-19 cases.

Biochemical Test

Specimen
Type

Clinical Significance

Abnormality
in COVID-19
Cases

Interpretation

Albumin

Serum

Useful for assessment of
nutritional status and liver
dysfunction

Decreased

Impairment of liver function,
malnourished

Increased

Dehydration

Lactate Dehydrogenase

Serum

Useful for assessment of tissue
damage

Increased

Indicate severe shock, and
hypoxia. Widespread tissue
damage particularly pulmonary
injury

Alanine
Aminotransferase
(ALT)

Serum

Useful for assessment of liver
dysfunction associated with
hepatic necrosis

Increased

Destruction of hepatocytes

Aspartate
aminotransferase (AST)

Serum

Useful for assessment of
myocardial infarction, acute liver
cell damage

Increased

Tissue damage, particularly
liver injury

Creatinine

Serum

Useful for diagnosing and
monitoring treatment of acute
and chronic renal diseases
-Estimation of Glomerular
filtration rate
-Adjusting dosage of renally
excreted medications

Increased

Renal injury, declining renal
function, therapeutic dose
adjustment

Procalcitonin

Serum

Useful for diagnosing Diagnosis
of bacteremia and septicemia

Increased

bacterial coinfection in those
developing severe form of
disease

C-reactive protein

Serum

Useful for detecting systemic
inflammatory processes

Increased

Increase associated with
severity of viremia and sepsis,
associated with prognosis

Lactate

Plasma

Useful for monitoring of lactic
acidosis

Increased

Septic Shock, associated with
prognosis

12
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AKUH Blood Bank During SARS-COV-2
Outbreak
Muhammad Hasan
Section of Hematology & Transfusion Medicine

Coronavirus disease 2019 (COVID‐19) is caused by
a novel coronavirus recently renamed as severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2).
It is transmitted primarily via droplets, respiratory
secretions and direct contact. The presence of the virus
in feaces and blood suggest other probable modes of
transmission. Since the start of this epidemic it had
been speculated that it has the potential to reduce the
supply of blood components and adversely affect blood
system activities. Blood services across the world,
therefore, took steps to assess, plan, and respond
appropriately and proportionately. AKUH blood bank
took the blow very early, when on 26th February
2020, the first patient of Pakistan was diagnosed with
SARS-CoV-2 infection in Karachi, resulted in the
closure of all schools in Sindh by the government. On
27th February, we had a well-planned annual blood
donation camp at one of the leading schools in Karachi
which got canceled at the eleventh hour because of the
school closure. That camp was promising to collect the
donation of at least 500 blood units.
To maintain safe and adequate blood supply during
this outbreak we took the following measures:
1. Reduce the potential risk of transmission
through the transfusion of blood
Transmission of a respiratory virus by transfusion
is theoretically possible, but unlikely based on
precedent. Any actions taken to reduce risk are
therefore precautionary.
On 19th March, in the pre-donation assessment, we
added the following questions to be asked from the
potential blood donors:
• Within the last 14 days, travel history of the donor
(traveled to Karachi from an outside country or
from inside country)
• Within the last 14 days, travel history of any
person who has been in close contact with the
donor (traveled to Karachi from an outside
country or from inside country)

• The donor has a fever within last 14 days
• Cough, cold, flu or sore throat in the last 14 days
If the answer to any of these questions is YES, he is
deferred from donating blood for 28 days.
Since March 2020, we have deferred a total of 335
blood donors out of which 35 donors were deferred
due to the above-mentioned points.
2. Alleviate the impact of reduced availability of
blood donors
The reduction of donor numbers during the outbreak
is a major risk for the blood bank. So, we considered
the sufficiency risk early to enable preparedness
and response. Blood donation numbers were closely
monitored so that measures can be taken quickly to
pre-empt any decline in donor attendance. Our aim
has been to balance donor deferrals for protecting the
blood supply with an estimate of any negative impact
on the adequacy of the blood supply. Furthermore,
we conveyed our concerns about the shortage of
blood supply to clinical areas and ask them to ensure
exchange donation by sending blood donors to the
blood bank, while arranging blood products for their
patients. At the time of writing, we have been able to
equilibrate the supply with demand. But as the month
of Ramadan has approached we fear a decrease in
the number of blood donations and working upon the
strategies to overcome it.
3. Mitigate the risk of staff and donor exposure to
SARS-CoV-2
Any transmission from a donor is far more likely
to occur through the respiratory route than through
parenteral routes (including phlebotomy during blood
donation). It is possible that an infected donor who
is asymptomatic, pre-symptomatic, or has very mild
symptoms may infect other donors and staff.
Besides following the standard laboratory biosafety
practices advised by laboratory management we
adopted the following workflow for blood donation:
13
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4. Collection of Convalescent Plasma
While specific new drugs and vaccines are being
researched for COVID 19, certain drugs that are
already present in medical arsenal are under trial
too. One investigational treatment being explored
for COVID-19 is the use of convalescent plasma

VOL 46, ISSUE 2
(CP) collected from recovered COVID-19 patients.
Convalescent Plasma is a source of passive immune
therapy- the administration of specific antibodies
against a given agent for preventing or treating
an infectious disease due to that agent. Section of
Hematology & transfusion medicine in collaboration
with Section of Infectious disease has started an
open-label clinical trial, in which we are collecting
plasma from the persons (CP donors) who have
been recovered from SARS-CoV-2 infection and
transfusing it to the patients having active severe
COVID-19, to assess the efficacy and safety of this
therapy.

Significance of COVID-19 Whole Genome
Sequencing
Samina Ghani
Molecular Pathology

Coronaviruses are a large family of single-stranded
RNA viruses that can infect humans as well as
animals. In humans, coronavirus infection is typically
associated with mild to moderate respiratory illnesses
such as the common cold Sometimes these viruses can
mutate and jump to humans, which results in severe
respiratory illness, as in the outbreak of Severe Acute
Respiratory Syndrome (SARS-CoV) in 2002 and, more
recently, Middle East Respiratory Syndrome (MERSCoV) in 2012. Coronavirus disease 2019 (COVID-19)
was discovered in Hubei Province, China in December
2019. Initially, the new virus was called 2019-nCoV.
Subsequently, the task of experts of the International
Committee on Taxonomy of Viruses (ICTV) termed it
the SARS-CoV-2 virus as it is very similar to the one
that caused the SARS outbreak (SARS-CoVs).
Coronavirus is an RNA virus consisting
of positive-sense single-stranded RNA of
approximately 27–32 kb. The genome encodes
27 proteins including an RNA-dependent RNA
polymerase (RdRP) and four structural proteins.
The four structural proteins include the spike
surface glycoprotein (S), small envelope protein
(E), matrix protein (M), and nucleocapsid protein
(N).
14

Single-stranded RNA genome of SARS-CoV2
Routine confirmation of COVID-19 cases is based
on detection of COVID-19 virus nucleic acid (RNA)
by real time RT-PCR assays. A major advantage of
real-time RT-PCR assays is that amplification and
analysis are done simultaneously in a closed system
to minimize false-positive results associated with
amplification product contamination.
Sequencing
Sequencing played an important role in identifying
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the novel coronavirus SARS-CoV-2. Following nextgeneration sequencing, where partial and full genomes
were obtained, Sanger sequencing was used in the
connection of viral contigs, resulting in acquisition
of the sequence of full length genomes. Additionally,
by analyzing these genomes and comparing to other
known coronaviruses, it was determined that the virus
originated in an animal reservoir that evolved from
bats, with a likely intermediate animal host. Whole
genome sequencing will help understand whether
multiple strains of Covid-19 exist among population
and dispersal patterns of mutations in various
geographic areas. Data generated through WGS may
predict effectiveness of the response to drugs and
variation from one strain to another.
Next-generation Sequencing (NGS)
During viral pandemics, next-generation
sequencing (NGS) is proven as a valuable tool for
the characterization and detection of viruses in the
environment, animals, and humans. The biggest
challenge during any outbreak is to predict the pattern
or evolution and disease spread, especially with RNA
viruses such as the Covid-19, which have a very high
genetic variability making it difficult to understand
the transmission pattern, number of active strains and
their geographical locations, or if a person is affected
with multiple strains. By sequencing the entire viral
genome, researchers can pinpoint the genetic changes
that occur in the virus as it spreads through the

VOL 46, ISSUE 2
population. This approach is useful to
1) Understand the transmission of the virus
Understanding changes in the genetic sequence of
the viral genomes collected from different patients
allows researchers to build a viral ‘family tree’ and
contribute to efforts to monitor disease spread within
and between populations over time. This can help
with identification of infection ‘hot spots’, or of super
spreaders – individuals who transmit the infection
to a larger than expected number of people. This
information is valuable for planning targeted public
health interventions to reduce disease spread.
2) Design treatments and vaccines
Understanding the viral DNA sequence will assist
researchers designing therapies and vaccines that
target specific features of the virus. It will also allow
better understanding of how therapy and vaccine
effectiveness might change as the virus evolves.
3) Monitor viral evolution
Continually tracking the virus will alert researchers to
genetic changes that might give rise to less virulent or
more virulent strains. Early warning of a more virulent
virus or emergence of treatment resistance will be vital
to support measures to minimize disease spread and for
designing new treatments and vaccines.

Convalescent Plasma Therapy for COVID-19
Dr Anila Rashid
Haematology & Transfusion Medicine

Convalescent plasma: Convalescent plasma refers to
plasma from an individual who has recovered from an
infection. It is a means of antibody transfer to provide
passive immunity until the individual can develop an
active immune response, with the hope that clinical
outcomes can be improved in the recipient. Convalescent
plasma is not routinely available, nor is it a licensed FDA
product; instead, it has been made available for specific
agents at times of disease epidemics or pandemics.
During the 2019-2020 coronavirus disease (COVID-19)

pandemic, community blood centers around the world
are establishing programs for recovered individuals
to donate convalescent plasma. Once the pandemic
subsided, convalescent plasma is likely to become
unavailable. Monoclonal antibodies with neutralizing
potential are another approach, although this requires
additional development and manufacturing steps.
Convalescent plasma is generally most appropriate
for individuals who are severely ill and do not have
access to better alternatives.
15
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Historical Use: Prior to SARS-CoV-2, convalescent
plasma was used for treating the following severe
acute respiratory syndromes
Coronaviruses and Convalescent Plasma Therapy
SARS-CoV (2003 SARS epidemic) – There was
reduced mortality (on the order of 7-23 percent lower
mortality). There was a reduced hospital length
of stay, especially when convalescent plasma was
administered within two weeks of symptom onset. No
major complications were reported.
Influenza viruses and Convalescent Plasma
Therapy
H1N1-pdm09 (2009 pandemic) – One study reported
an 80 percent reduction in mortality, especially
with early treatment. There was a reduced length of
intensive care stay.
H5N1 (avian influenza; several outbreaks) – Nonsignificant benefits (one study).
H1N1 (1918-1919 flu epidemic) – There was reduced
mortality (approximately 20 percent reduction).
Convalescent blood was used rather than plasma.
Plasma Administration – Criteria for optimal
preparation of plasma (or hyperimmune globulin)
include
l High enough titer of neutralizing antibody to be
effective
l Lack of infectious particles (either the target 		
pathogen or others)
l Blood type compatible (ABO; Rh in women of
reproductive potential)
l Evidence for efficacy and lack of harm, ideally from
randomized trials or prospective studies
l Informed consent with discussion of the risk of
disease and risks and benefits of therapy
Risks of exposure to plasma include infection;
volume overload and febrile, allergic, anaphylactic
transfusion reactions, and transfusion-related acute
lung injury (TRALI).
Patient Eligibility: The use of COVID-19
convalescent plasma to treat patients includes the
following criteria:
l
Laboratory confirmed COVID-19
l
Severe or immediately life-threatening COVID-19
m Severe disease is defined as one or more of
16
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		the following:
n
shortness of breath (dyspnea),
n
respiratory frequency ≥ 30/min,
n
blood oxygen saturation ≤ 93percent,
n
lung infiltrates > 50 percent within 24
				 to 48 hours
m Life-threatening disease is defined as one or
		 more of the following:
n
respiratory failure,
n
septic shock,
n
multiple organ dysfunction or failure
COVID-Donor Eligibility
COVID-19 convalescent plasma must only be
collected from individuals who meet all routine donor
eligibility requirements. Donation testing for relevant
transfusion-transmitted infections must be performed
and the donation must be found suitable. COVID-19
convalescent plasma is collected from individuals
who meet the following qualifications:
l
Evidence of COVID-19 documented by a 		
laboratory test either by:
1. A diagnostic test (e.g., nasopharyngeal swab)
		 at the time of illness OR
2. A positive serological test for SARS-CoV-2
		 antibodies after recovery, if prior diagnostic
		 testing was not performed at the time
		 COVID-19 was suspected.
Either one of the following
1. Complete resolution of symptoms at least 28
		 days prior to donation
2. Complete resolution of symptoms at least
		 14 days prior to donation, AND Negative
		 results for COVID-19 either from one or more
		 nasopharyngeal swab specimens or by a
		 molecular diagnostic test from blood.
l

SARS-CoV-2 neutralizing antibody titers, if
available
1. Neutralizing antibody titers of at least 1:160.
		 A titer of 1:80 may be considered acceptable
		 if an alternative matched unit is not available.
2. When measurement of neutralizing antibody
		 titers is not available, consider storing a
		 retention sample from the convalescent
		 plasma donation for determining antibody
		 titers at a later date.
l

Source: UpToDate April 11, 2020, https://www.fda.gov/vaccines-bloodbiologics/investigational-new-drug-ind-or-device-exemption-ide-processcber/recommendations-investigational-covid-19-convalescent-plasma.
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Optimizing the Availability and Rational Use
of Personal Protective Equipments (PPES)
Among Health Care Workers
Dr Moiz Ahmed Khan
Clinical Microbiology

Frontline health care workers involved in the
screening process and providing care for COVID-19
patients are playing a pivotal role in mitigating the
effects of the disease in the community. Hence,
prioritizing the protection of health care workers
is of utmost importance by prompt provision of all
essential PPEs. Currently overwhelming demand and
scarce supply of PPEs has created a serious threat to
frontline workers across the globe. It has now become
an essential responsibility of any institute to lay down
strategies that ensure prompt and regular availability
of PPEs as well their rational use. For the effective
utilization required Risk assessment. Following are
the generic recommendations for the usage of PPE
during COVID pandemic among health care workers:
Setting

Target personnel or
patients

Screening

Health care workers

Clinical triage
for prioritization
of care according
to severity (e.g.
Manchester
classification)
should be performed
in separate area for
individuals with
symptoms and signs

Patient room/ward

Patients with
symptoms suggestive
of COVID-19

Activity
Preliminary
screening not
involving direct
contact.

Any

1) The type of PPE used will vary according to the
setting, type of personnel, and activity (require
risk assessment).
2) Those involved in direct care of COVID-19
patients should use PPE according to indications.
3) For aerosol-generating procedures and support
treatments (tracheal intubation, noninvasive
ventilation, tracheotomy, cardiopulmonary
resuscitation, manual ventilation before
intubation, and bronchoscopy) use respirators, eye
protection, gloves and gowns; aprons should also
be used if gowns are not fluid-resistant.
Recommended PPE during the outbreak of COVID-19
outbreak, according to the setting, personnel, and type
of activity:
Type of PPE or procedure

•
•
•
•
•
•
•

•
Patients without
symptoms suggestive
of COVID-19

Any

Health care workers

Providing
direct care to
COVID-19
patients, in
the absence
of aerosolgenerating
procedures

•
•
•
•
•
•
•

Maintain physical distance of at least 1 meter.
Ideally, build glass/plastic screens to create a barrier
between health care workers and patients
No PPE required.
When physical distance is not feasible and yet no patient
contact, use mask and eye protection.
Maintain physical distance of at least 1 meter.
Provide medical mask if tolerated by patient.
Immediately move the patient to an
isolation room or separate area away from
others; if this is not feasible, ensure spatial distance of
at least 1 meter from other patients.
Perform hand hygiene and have the patient
perform hand hygiene
No PPE required
Perform hand hygiene and have the patient
perform hand hygiene
Medical mask
Gown
Gloves
Eye protection (goggles or face shield)
Perform hand hygiene

17
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Laboratory
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Target personnel or
patients

Activity

Health care workers

Providing direct care
to COVID-19 patients
in settings where
aerosol- generating
procedures are
frequently in placeii

Cleaners

Entering
the room of
COVID-19
patients

Entering the
room of a
COVID-19
patient

Lab technician

Manipulation of
respiratory samples
Specimen handling
for molecular testing
would require BSL2 or equivalent
facilities.
Handling and
processing of
specimens from
cases with suspected
or confirmed
COVID-19 infection
that are intended
for additional
laboratory tests,
such as hematology
or blood gas
analysis,
should apply standard
precautions
Administrative
tasks that do not
involve contact with
COVID-19 patients.

In the scenario of severe shortage of PPE despite
application of the above-mentioned strategies, it
is crucial to ensure to protect frontline health care
workers. This includes urgent increased production
of PPE, including, if needed, through advance market
commitments, public-sector mandated scale up of

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Visitors

Administrative areas All staff, including
health care workers.

18

Type of PPE or procedure
Respirator N95 or FFP2 or FFP3 standard, or equivalent.
Gown
Gloves
Eye protection
Apron
Perform hand hygiene
Medical mask
Gown
Heavy-duty gloves
Eye protection (if risk of splash from organic
material or chemicals is anticipated)
Closed work shoes
Perform hand hygiene
Maintain physical distance of at least 1 meter
Medical mask
Gown
Gloves
Perform hand hygiene

•
•
•
•
•
•

Maintain physical distance of at least 1 metre
Medical mask
Eye protection
Gown
Gloves
Perform hand hygiene

•
•
•

Maintain physical distance of at least 1 metre
No PPE required
Perform hand hygiene

production by the private sector, pursuing donation
options, international solidarity through financial
support of PPE purchase and distribution for the needs
of the most vulnerable countries, and engaging with
the general public to prevent irrational use of PPE at
community level, among other strategies.
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Setting

Target personnel or
patients

Screening/triage

Health care workers

Activity
Preliminary
screening not
involving direct
contact

Type of PPE or procedure

•
•
•
•
•

Patients with
symptoms suggestive
of COVID-19

Any

Patients without
symptoms suggestive
of COVID-19

Any

•
•
•
•
•

Maintain physical distance of at least 1 metre.
Ideally, build a glass/plastic screen to create a
barrier between health care workers and patients
No PPE required
When physical distance is not feasible and yet no
patient contact, use mask and eye protection.
Perform hand hygiene
Maintain spatial distance of at least 1 metre.
Provide medical mask if tolerated.
Perform hand hygiene
No PPE required
Perform hand hygiene

Grand Exit of The World’s Famous Pandemics
Dr Tamana Asghari and Dr Khurram Minhas
Histopathology

With the human race constantly evolving and
improvising through the ages, the microorganisms
did not seem to have been left behind at all. Infact,
every few decades they make sure to make their
presence felt (not that they need to) globally by
making a magnanimous entry and a grand exit.
Pandemics have been mankind’s oldest enemy, the
earliest reported pandemic dates back to 165 AD and
was known as Antonine Plague. At a glance, all of
these pandemics have maintained their individuality
in terms of causative organisms, their vector, mode of
transmission, signs and symptoms etc. But that one
thing that has been unanimously followed by them
is the mass death they caused before finally saying
Ciao! Here are few of the famous pandemics and their
unforgettable exits:
1. Plague Of Justinian- No one left to die:
With its arrival in Constantinople in 541 CE after the
plague-ridden fleas hitched a ride on the black rats
that snacked on the grain, this pandemic which got
its name from a land conquered by Emperor Justinian
over the Mediterranean Sea spreaded over Europe,
Asia, North Africa and Arabia killing an estimated
30 to 50 million people, perhaps half of the world’s
population.
Causative organism: Yersinia pestis.
Estimated death: 30-50 million.

2. Black Death- The invention of Quarantine:
800 years later Yersinia pestis made an impactful
comeback and this time with quite a grim name The
black death, it hit Europe in 1347 and finally bid
adieu in 1351 with a death of 200 million people on
its name. Though it is said to have killed more people
than WWII, it did brought the idea of Quarantine as
a saviour. Imposed by Venetian laws as “terentino”,
it was first implemented on the arriving sailors for
30 days and was later extended to 40 days forced
isolation.
Causative organism: Yersinia pestis.
Estimated death: 200 million.
3. The great Plague of London- Sealing up the
sick:
The plague didn’t seem to leave the British capital
the easy way and it experienced around 40 outbreaks
in 300 years (1348-1665) killing 20 percent of its
population. As the saying goes desperate times call
for desperate measures, the Englishmen started
separating and isolating the sick, homes stricken by
plague were marked with a bale of hay strung to a
pole outside. The family members of the infected
person had to carry a white pole when out in public,
cats and dogs were massacred since they were
believed to carry the disease and the dead were buried
in mass graves. Red crosses were painted on their
19
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doors along with a plea for forgiveness: “Lord have
mercy upon us”.
Causative organism: Yersinia pestis.
Estimated death: 100,000 people in seven months.
4. Smallpox- The first vaccine:
Smallpox was endemic to Europe, Asia and Arabia
for centuries but its arrival in 15th century with
the European exploreres bought devastation to the
indigenous population of US and Mexcio. 90 to 95
percent of the indigenous population of Americas
were wiped out over a century and the population of
Mexico went down from 11 million to one million.
18th century saw the coming of smallpox vaccine
in quite a dramatic way, a British doctor Edward
Jenner, after learning that the milkmaids who were
infected with cowpox virus were immuned to
smallpox, inoculated his gardener’s nine year old son
with a milder cowpox virus before exposing him to
smallpox and voila!! In 1980 WHO finally declared
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the complete eradication.
Estimated death: 56 million.
5. Cholera- A new way into public health research:
Tens of thousands became prey to Cholera in early
to mid19th century in England. The then theory of it
being spread by foul air prompted Dr John Snow that
there was more to this rapidly fatal disease than what
meets the eye. And with his integrated investigations
of hospital records, morgues and precise location of
outbreak, the Broad Street pump for drinking water
was found to be the culprit behind the outbreak that
claimed 500 lives in just over 10 days. Though cholera
is still prevalent in some parts of third world countries
lacking proper sanitization but the overall education
of urban sanitization has been widely accepted by
many.
Causative organism: Vibrio cholera.
Estimated death: Approximately one million.

COVID-19 & Risk assessment for Clinical
Chemistry Procedures
Ms. Iffat Arman and Dr Hafsa Majid
Clinical Chemistry

Risk assessment is a systematic process of
collecting data and evaluating the likelihood and
outcomes of exposure to workplace hazard(s) and
so that appropriate risk control measures can be
implemented to reduce the risk to an acceptable
level. It is recommended to start with performing
a local risk assessment for each process step, that
is, from sample collection to testing and reporting.
Certain hazards will then be considered for each
process step, such as aerosol exposure or eye splash
during sample processing; infectious biological
specimen spill or leakage that can elevate the
level of risk. For each identified risk, appropriate
risk control measures should be selected and
implemented, to mitigate the residual risks to an
acceptable level.
In the context of SARS-CoV-2 pandemic, a risk
assessment exercise was done for processes
20

and procedures that are performed in Section of
Chemical Pathology. The exercise was led by
the Sectional safety officer, faculty and manager.
The team reviewed the laboratory processes and
procedures to identify the potential hazards,
followed by evaluation of the risk associated
with all procedures and control measures which
can be implemented to avoid risk to our staff.
A risk control strategy was developed based on
international guideline and strategies on biosafety
and biosecurity. Once these control measures
were implemented another review was carried
out by the team to again assess the risk.Different
types of specimen received at the Section of
Chemical Pathology are shown in table 1. It is
recommended that all laboratories should perform
risk assessment activities to assess and mitigate the
risks associated.
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Table 1: Types of Specimen, High Risk Activities and Risk Mitigation Strategies (Taken from WHO-Laboratory testing for
coronavirus disease (COVID-19) in suspected human cases. Interim guidance, 19 March 2020)
Specimen Type

High Risk Activities and
Concentration of virus

Risk Mitigation strategies adopted

Serum/Plasma/
Whole blood
Specimen

Low viral concentration.
Centrifugation is a risk
for aerosol generation.

n

CSF Specimen

highly infectious1

Urine Specimen

Not established yet2

Fecal Specimen

highly infectious

Breath Specimen

highly infectious

Sweat specimen

highly infectious

n
n
n

2

n

n

Within-lab movement and non-essential handling/processing minimized
All samples treated as potentially infectious, wear surgical mask, gloves and
full sleeves gowns at all times
After centrifugation, wait for 10 minutes before opening the centrifuge.
In case of Breakage follow the defined protocol
While handling breath and fecal specimen, Perform sample processing/analysis
in Biosafety cabinets.
While collecting/processing/analyzing fecal/breath/sweat specimen: treat all
samples as infectious, wear N-95 mask, goggles, double gloves and full sleeves
gowns.
Liquid waste disposal process: use 5% Hypochlorite, to prevent splash exposure
wear face shields, surgical mask, full sleeves gowns and handle carefully.

1. Earlier studies on COVID-19 from Wuhan China have reported cases where specific SARS-CoV-2
RNA was not detected in the nasopharyngeal swab but was detected in a CSF
(https://doi.org/10.1016/.ijid.2020.03.062)
2. Duration and frequency of shedding of COVID-19 virus in stool and potentially in urine is unknown. 		
However warlier reports of COVID-19 have reported that shedding and thereby transmittance of virus is
through oral–fecal route (https://www.tandfonline.com/doi/full/10.1080/222 21751.2020.1729071)

Safety Considerations in the Laboratory
Testing of Specimens Suspected or Known
to Contain the Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2)
Sony Siddiqui
Molecular pathology

Emergence of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) causing
coronavirus disease 2019 (COVID-19), the World
Health Organization and the Centers for Disease
Control and Prevention (CDC) has released
documents to provide interim biosafety guidelines
for the collection, handling, and testing of clinical
specimens that might contain SARS-CoV-2.
WHO guidelines suggests all specimens (swabs,
body fluids, blood, feces) must be considered as
potentially infectious, and appropriate PPE must be
donned. However Prior studies on the coronaviruses
showed that a much lower concentration of the virus

was noted in stool, urine, and blood so the risk to the
laboratorian can be mitigate while using standard
blood borne pathogen biosafety level (BSL)–2
precautions. Aerial transmission is considered the
major exposure risk to the coronaviruses such as
SARS-CoV-2 however currently information is still
not available to define specifically the infectious
dose for SARS-CoV-2. As a standard for any
laboratory biosafety program, it is also important
to realize that the first step to consider is to identify
hazards by performing a biological risk assessment
as described below:

21
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Table 1: Simplified Biological Risk Assessment
Focus

Processes

Risk characterization

Identify hazards: Classify the potential for exposure (mode of transmission, organism concentration,
virulence, potential for spill or inhalation) ,determine likelihood and consequence of a specific risk)

Risk mitigation strategies

Identify required safety practices to address the risks (PPE, engineering controls, training, operating
procedures)

Workforce

Assess competency and experience of laboratory personnel Identify an appropriate training program
Enroll staff in an occupational health program

The CDC suggests standard practices used in the
laboratory during the manipulation of potentially
infected specimens performed in a certified class
II BSC within the BSL-2 laboratory, appropriate
physical containment devices should be used such
as centrifuge with safety buckets or sealed rotors,
eye and face protection, double gloves, and fit-tested
N95 respirator or surgical mask if N95 respirator
is not available. These Standard precautions should
be applied for aliquoting or diluting specimens,
inoculating bacterial or mycological culture media,
performing diagnostic tests that do not involve
propagation of viral agents in vitro or in vivo, nucleic
acid extraction procedures involving potentially
infected specimens, and preparation of chemical or
heat fixing of smears for microscopic analysis.

characterization of viral agents recovered in cultures
of SAR2-CoV specimens, the CDC suggests that
work should be performed in a BSL-III laboratory
while using BSL-III practices (to include fit-tested
N95 respirators or powered air-purifying respirators).
In general, while working within the laboratory
environment, regulatory standards require that all
health care facilities provide the appropriate personal
protective equipment (PPE) for the laboratorians,
that personnel be instructed in the proper use of this
PPE, the equipment being used in the laboratory
be maintained and safe, and written procedures for
the procurement, transportation, and handling of
patient specimens be available. Basic Core Processes
to Support Laboratory Biosafety Practices are
summarized as follows:

For virus isolation in cell culture and initial
Topic

Processes to Consider

Training

Donning and doffing of PPE, specimens collection, Packaging and shipping , waste management

Equipment

Certified BSC, Centrifuge with sealed rotor or safety cups

Inventory control

Adequate supply of specimen collection devices ,disinfection material, transport materials

Communication

Open lines with the medical care team Collaborations in place with the state/local public health
laboratory

From the standpoint of the histopathology laboratory,
the processing of frozen sections from a possible case
of COVID-19 should be performed only in a cryostat
where aerosols can be contained while wearing the
appropriate PPE. Any SARS-CoV-2 specimens that
have been formalin fixed and paraffin embedded,
however, should be inactivated based on the previous
information reported for the inactivation of SARSCoV.
The recommendations are often fluid when
responding to a new pathogen, strict adherence to
the suggested safety practices may not be the best
approach and should be based on the needs of the
22

specific facility. As a part of this process, each
laboratory should conduct a facility-specific risk
assessment that reviews the procedures performed,
identifies the hazards involved in the processes and
procedures, determines the competency level of the
personnel who perform the procedures, and evaluates
the equipment and facility design.
Summarized from
Peter C. Iwen, Karen L. Stiles, SM, Michael A.
Pentella. Safety Considerations in the Laboratory
Testing of Specimens Suspected or Known to Contain
the Severe Acute Respiratory Syndrome Coronavirus
2 (SARS-CoV-2).Am J Clin Pathol 2020; XX:1–4 DOI:
10.1093/AJCP/AQAA047
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Autopsy Findings in COVID-19 Deceased
Patients
Dr Sahar Suleman and Dr Nasir Ud Din
Section of Histopathology

“The key question: did the patient die from
COVID-19 or with COVID-19?” pointed out by
Dr Sanjay Mukhopadhyay (Director, Pulmonary
Pathology at Cleveland Clinic) in this recent research
study. It comprised of complete, comprehensive,
detailed autopsy reports of two COVID-19 deceased
patients in Oklahoma, USA, it is first of its kind
report published in an English-language peerreviewed journal. Earlier Chinese literature review
based on postmortem lung core biopsies, from
COVID-19 patients have all described similar
histopathological changes including Diffuse alveolar
damage (DAD) in most , with superimposed
bacterial pneumonia in one and several nonspecific
changes like edema, patchy inflammation, exudates
(fibrinous/proteinaceous), mononuclear inflammatory
infiltrates, giant multinucleated cells etc. The
objective of this study was to offer insight based on
complete autopsy on underlying pathology. After
proper biosafety and infection control practice
Oklahoma forensic pathologists with adequate PPE
conducted the autopsies.

The first decedent was a 77-year-old male known
case hypertension, Deep venous thrombosis
(DVT), status post total knee replacement (TKR),
cholecystectomy and splenectomy, with complaints
of fever and chills for 6 days. There was no travel
or exposure history. He experienced shortness of
breath, suffered sudden cardiac arrest during transfer
to urgent care, and died soon after reaching the
hospital. Postmortem nasopharyngeal swabs and
lung parenchymal swabs were positive for SARSCoV-2, however basic respiratory pathogen panel
was negative. Histological findings in the lungs
revealed patent airways, no mucus plugging, DAD
with hyaline membrane formation and mild chronic
interstitial inflammation comprising of mainly
lymphocytes in airway mucosa. T-lymphocytes
were positive by immunohistochemistry for CD3,
CD4 and CD8. Other significant findings were
coronary artery disease with no myocarditis,
arterionephrosclerosis, and a right renal mass
(oncocytoma).

A

B

Figure 1A. Diffuse alveolar damage in the acute
stage. Note hyaline membranes (arrow). B). Patchy
interstitial chronic inflammation. This image is
taken from one of the few areas where interstitial
inflammation was obvious even at low magnification.
In most areas, the inflammatory infiltrate was very
sparse or absent.

The second decedent was a 42-year-old male known
case of myotonic muscular dystrophy, status post
cholecystectomy. He had a short history of fever,
cough and shortness of breath, no travel or exposure
history. Two days before his demise he started having
abdominal pain. CT chest preceding death showed
bilateral ground-glass opacities and consolidations.
23
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However, he passed away due to cardiac arrest after
few hours in hospital. Postmortem nasopharyngeal
swabs were positive, and lung parenchymal swabs
were negative for SARS-CoV-2. Basic respiratory
pathogen panel was negative but bacterial cultures
were positive for nontoxigenic Escherichia coli,
Proteus mirabilis, and Candida tropicalis. Histological
findings in the lungs revealed airspaces filled
by mixture of neutrophils and histiocytes (acute
bronchopneumonia) with rare aspirated vegetable
particles. No DAD or airway mucus plugging. IHC
results were same as case1 along with CD68 positive
macrophages. Other findings were liver cirrhosis,
gynecomastia, testicular atrophy, nephrosclerosis,
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mild coronary atherosclerosis no myocarditis.
The authors concluded that patients may occasionally
die of other disease processes although being positive
for COVID-19 as illustrated in case two; who “died
of acute bacterial bronchopneumonia likely caused
by aspiration, therefore, this patient likely died with
COVID-19, not from COVID19”. The reports also
denied presence of viral myocarditis which is being
currently speculated by community of physicians.
They believe these autopsies has allowed adequate
collection of involved tissue hence increasing
accuracy of reporting, also multiple organs can be
assessed simultaneously.

Donning, Doffing and Fit Testing of N95
Respirators
Dr Joveria Farooqi
Clinical Microbiology

In the advent of the COVID-19 pandemic, various
biosafety precautions have been advised for healthcare
workers. One of these precautions is the use of N95
respirators while working in a situation where there
is a possibility of exposure to aerosols, i.e. droplets
smaller than 1.0 micron in size that do not settle down
within three feet of the patient. This may occur while

suctioning airways, intubating patients, being in a
room with an intubated patient collecting respiratory
samples, or centrifuging clinical material which may
contain the virus. The N95 respirators are so named
because they can the filter or prevent the passage of
>95 percent particles 0.3 microns or more in size.

Donning N95 Respirators
The steps of donning the N95 mask are as given in Table 1
Step 1: Check integrity of the mask.

Step 2: Perform hand hygiene before touching the mask. Hold
the mask in the palm of your hand with the straps hanging
below.
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Mask must not be cracked, wet, folded or soiled. The mask must
seal well (Step 5)
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Step 3: Position the mask in front of your face, covering nose
and mouth, with straps hanging over your hand

Step 4: Move the top strap over your head and above your ear,
move the lower strap below your ear around the neck.

Step 5: Using index and middle fingers of both hands press
down on the metal bit on the bridge and mold it according to the
shape of your nose and facial structure. Do not pinch the bridge
as it can tent the mask and result in leaking.

Step 6: Test the mask for leakage or seal by placing your hands
around the edge and exhaling. If you feel air leak from the
bridge, press down on the metal bit and retest for leakage. If
air leaks from the sides, adjust the straps till a proper seal is
achieved. The mask edges should be sealed to your face and no
air should leak from them if the efficiency of the mask is to be
ensured.
Seal test must be performed every single time the mask is
worn.

25
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Fit-testing
To confirm if the make of N95 is actually appropriate
for you and it really is sealing well to your face, fit
test may be performed. If fit-test is passed, it remains
valid as long as the make of the mask does not
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change, and the individual does not have any great
change in facial structure due to accident, surgery
or significant change in weight. A fit-testing kit is
required to perform a fit test.

The steps of fit-testing are given in Table 2
Step 1: The person being tested should not have ingested
anything in the last 30 minutes. Sensitivity of the taste
receptors of the person being tested is checked by administering
a puff of the diluted reagent through a hand-held nebulizer (both
provided in the kit) while wearing a hood over their head. This
reagent may be sweet (saccharin) or bitter (Bittrex) in taste. The
individual is asked if they can taste the reagent; if not, another
puff is administered every 20 seconds till the person can taste
it or 20 puffs are complete. The person is asked to remember
the taste, then asked to gargle and rinse out the taste completely
from their mouth.
If the reagent cannot be tasted after 20 puffs, the fit test cannot
be performed for this person using this reagent, it may be
attempted with another reagent eliciting an alternate taste.

Courtesy: 3M™ FT-10 (sweet) and 3M™ FT-30 (bitter) Qualitative Fit
Testing Kits. https://youtu.be/PthSES4O9d8

Step 2: Ask the person being fit-tested to don the N95 and
seal test it. Now place the hood over the person’s head and
administer five puffs of the undiluted fit-testing reagent and ask
them to breathe normally for 30 seconds. Ask them to indicate
if they can sense the taste they were sensitized with. If yes, the
fit test has failed, ask them to remove mask rinse mouth repeat
donning and seal test and restart from step 2. If they cannot
taste it, proceed to next step.9
Step 3: Administer another five puffs of reagent and ask the
person being tested to take deep breaths for 30 seconds. If they
can still not taste the reagent, then proceed to step 3. If they
can, then doff mask, rinse out taste, and repeat from step 2.
Step 4: Administer another five puffs of reagent and ask the
person being tested to move their head side to side and up and
down, bend at the waist, reach up and to the side in measured
movements. Continue these movements for 30 seconds. If they
can still not taste the reagent, then proceed to step 5. If they
can, then doff mask, rinse out taste, and repeat from step 2.
Step 5: Administer another five puffs of reagent and ask the
person being tested to talk continuously for 30 seconds. You
may keep a written passage for them to read out. If they can still
not taste the reagent, then fit test is passed. If they can, then doff
mask, rinse out taste, and repeat from step 2.
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Fit testing being performed in Aga Khan University Hospital, Karachi.

JUNE 2020

VOL 46, ISSUE 2

Doffing N95 respirators
The steps of doffing the N95 mask are as given in Table 3
Step 1: Perform hand hygiene and hold the lower strap from the
back and pull it off
Step 2: Pull the upper strap from the back and pull it over the
head

Step 3: Hold the mask from the straps and store in a paper bag
labeled with your name or discard if soiled, cracked or wet.
Perform hand hygiene.

Personal Protective Equipment (PPE)
for Coronavirus Disease (Covid-19)-As
Recommended by World Health Organization
Dr Shayan Sirat
Radiology

In this era of COVID-19 pandemic, it has been a
challenge to fight this novel virus efficaciously without
compromising well-being of health professionals. The
frontline healthcare providers and staff, who are in direct
contact with the patient or deal with Aerosol Generating
Procedures (AGP) have high risk of transmission of this
infection and therefore need effective protection. Below
is the summary of the rational use of personal protective

equipment (PPE) for coronavirus disease (COVID-19)
as proposed by WHO on 19th, March 2020 for health
care and community setting. Though these are interim
guidance but have been well formulated to achieve
maximum protection. PPE includes gloves, medical
masks, goggles or a face shield, and gowns. For specific
procedures, respirators (i.e. N95 or FFP2 standard or
equivalent) and aprons. (Figure 1)
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Preventive Measures for COVID-19 Disease
Based on the available evidence, the COVID-19 virus
is transmitted between humans through droplets and
close contact. There is no airborne transmission.
Personnel in close contact or caring for COVID-19
patient are at most risk of contracting infection.
Preventive and attenuating measures are key.
The most effective preventive measures in the
community include:
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• Wearing a medical mask if you have
		 respiratory symptoms and performing hand
		 hygiene after disposing of the mask;
• Maintaining social distance (a minimum
		 of 1 meter = 3 feet) from persons with
		respiratory symptoms.
Additional precautions to be taken by frontline health
care workers includes using PPE appropriately; this
involves selecting proper PPE and being trained in
how to put on, remove, and dispose of it. Besides PPE,
administrative and environmental and engineering
controls, has also been described in WHO’s Infection
prevention and control of epidemic- and pandemicprone acute respiratory infections in health care.
These controls are summarized here.
Administrative controls include safeguarding
resources for infection prevention and control
(IPC) measures, such as appropriate infrastructure,
development of clear IPC policies, facilitated access to
laboratory testing, appropriate triage and placement of
patients, adequate staff-to-patient ratios, and training
of staff.
Environmental and engineering controls aim at
minimizing the spread of infection and pollution
of surfaces and inanimate objects. They include
providing adequate space to allow physical distance of
at least one meter (three ft) to be maintained between
patients and between patients and health care workers
and assuring availability of well-ventilated isolation
rooms for patients with suspected or confirmed
COVID-19.

Figure 1: Personal protective equipment, https://www.usatoday.com/
in-depth/news/2020/03/31/coronavirus-protection-what-health-careworkers-need-stay-safe/2917179001/

• Performing hand hygiene frequently with an
		 alcohol-based hand rub if your hands are not
		 visibly dirty or with soap and water if hands
		are dirty;
• Avoiding touching your eyes, nose, and
		mouth;
• Practicing respiratory hygiene by coughing
		 or sneezing into a bent elbow or tissue and
		 then immediately disposing of the tissue;

Recommendations for optimizing the availability
of PPE. In view of the global PPE shortage, the
following strategies can facilitate optimal PPE
availability (Figure 2).
Minimize PPE
need
Coordinate
PPE supply
chain

Use PPE
appropriately

Optimize PPE
availability
Figure 2: Strategies to optimize the availability of PPE
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1. Minimize the need for PPE:
The following interventions can minimize the need
for PPE while protecting health care workers and
others from exposure to the COVID-19 virus in health
care settings.
• Prefer using telemedicine to evaluate
		 suspected cases of COVID-19.
• Use physical barriers such as glass or plastic
		 windows, in areas such as triage, the
		 registration desk and pharmacy window to
		reduce exposure.
• Health care workers not involved in direct
		 care of COVID-19 patients should be
		 restricted from entering the isolation rooms.
• To minimize the number of times a room
		 is entered, consider bundling activities e.g.
		 check vital signs during medication
		 administration or have food delivered by
		 health care workers while they are performing
		other care.
• Ideally, visitors shall not be allowed, but
		 if unavoidable, restrict the number of visitors
		 to isolation areas; reduce the amount of time
		 visitors are allowed to spend in the area; and
		 provide clear instructions about how to put on
		 and remove PPE and perform hand hygiene to
		 ensure that visitors avoid self-contamination.
2. Ensure PPE use is rational and appropriate:
PPE should be used based on the risk of exposure
(e.g. type of activity) and the transmission dynamics
of the pathogen (e.g. contact, droplet or aerosol). The
overuse of PPE will have a further impact on supply
shortages. Following recommendations, if observed,
will ensure rational use of PPE.
• The type of PPE used when caring for
		 COVID-19 patients will vary according to the
		 setting and type of personnel and activity
		(Table 1).
• Health care workers involved in the direct
		 care of patients should use the following PPE:
		 gowns, gloves, medical mask, and eye
		 protection (goggles or face shield).
• Specifically, for aerosol-generating
procedures (e.g. tracheal intubation,
non-invasive ventilation, tracheostomy,
cardiopulmonary resuscitation, manual
ventilation before intubation, bronchoscopy)
health care workers should use respirators,
eye protection, gloves and gowns; aprons
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Table 1 Recommended PPE during COVID-19 outbreak
Health care workers
-providing direct care to
COVID-19 patients- medical
mask, gown, gloves, eye
protection (goggles or face
shield)

Health care workers
- aerosol-generating
procedures performed on
COVID-19 patients- respirator
N95 or FFP2 standard, or
equivalent, gown, gloves, eye
protection, apron.

Cleaners- entering the
room of COVID-19 patientsmedical mask, gown, heavy
duty gloves, eye protection
(if risk of splash from organic
material or chemicals) boots
or closed work shoes.

Visitors- entering the room
of a COVID- 19 patientmedical mask, gown, gloves.)

should also be used if gowns are not fluid
resistant.
In addition to using the appropriate PPE, frequent
hand hygiene and respiratory hygiene should
always be performed. PPE should be discarded in
an appropriate waste container after use, and hand
hygiene should be performed before putting on and
after taking off PPE.
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Radiology Department Preparedness for
COVID-19
Dr Ismail Alvi and Prof Tanveer ul Haq
Radiology Department.

The Coronavirus Disease 2019 (COVID-19) pandemic
began in December 2019 in Wuhan, China. The
outbreak is due to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection. In March
2020, the World Heath Organization declared
COVID-19 as a pandemic, due to the rapid increase in
the number of cases outside China.
Due to the nature of the outburst in China, Chest
CT findings (e.g., peripheral ground-glass infiltrates
and/or organizing pneumonia) temporarily became
part of official diagnostic criteria of COVID-19 as a
substitute for viral nucleic acid testing. In addition
to COVID-19, Radiology departments have to cater
a large number of other patients and make sure that
there is no infection spread from the confines of
the department, while maintaining high quality of
diagnostic and interventional services.
AIMS
Radiology department, according to the Hospital
infectious disease department prepared a set of
policies and procedures tailored to department’s
needs.
The aims were
a) to reduce patient morbidity and mortality
		 related to infection through early diagnosis
		 and appropriate treatment
b) to prevent disease dissemination to our 		
		 employees, patients and the general
		community.
c) to maintain radiology diagnostic and
		 interventional services for the entirety of the
		 hospital and health system.
Outpatient Services
With the guidelines of the infectious disease
department, radiology department setup patient
screening desk (Figure 1) at the entrance of
department, where screening of all patients and
30

visitors in carried out. A second layer of screening for
symptoms is carried out at the radiology front desk.

Figure 1 - Screening desk at Radiology Entrance.

Patient screening is also undertaken at the time of
radiology exam scheduling on phone. For elective
radiology exams, suspected patients are referred to
the designated hospital screening area (initially CHC)
for further workup. In addition to patient screening
this desk helps in enforcing the ‘one patient one
attendant’ policy.
Furthermore, radiology department has limited
the number
of elective
appointments
to ensure
that social
distance can
be maintained
during
department
stay. This
is being
accomplished
via automated
patient texting
services, direct
calls to patients
from radiology
Figure 2 - Safe Distance Floor markers at Radiology Reception
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appointment desk and through Radiology coordinator
assistance. The seating arrangement (Figure 2) in the
waiting areas have also been transformed to ensure
social distancing.
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can be made moreover we have assigned the pathway
through which we transport the patient to radiology
so our elective patients are not exposed with these
population and GR,US, CT and MRI system to
provide services for these patients.

Figure 3 - Waiting area with distant seating

Inpatient and ER Services
After coordination with inpatient areas, all radiology
requests should mention COVID status of the patient
in one of the following categories.
a) Negative for COVID-19.
b) Suspected for COVID-19.
c) Positive for COVID-19.
Separate procedure rooms in all modalities (x-rays,
CT-scan, MRI) are allocated for negative and
suspected/positive patients for COVID-19. Similarly,
separate portable X-Ray and Ultrasound machines are
designated for COVID areas and general inpatients.
Imaging of COVID-19 Positive or Suspected
Patients

Figure 4 - Housekeeping staff cleaning with hypochlorite solution.

Implementation of “social distancing” strategies
for Staff, Trainees, and Faculty
The radiology reading room has been restructured
to promote social distancing (Figure 5). A number
of diagnostic workstations have been shifted to other
locations (like radiology library, teaching room,
etc.) so that social distancing can be practiced easily.
The reading room is equipped with hand sanitizers
and alcohol wipes (Figure 6) for disinfection of the
computer peripherals (microphone, keyboard, mouse).

The decision to image patients who are COVID-19
positive or suspected is based on how the imaging
will impact patient care. Currently we do not routinely
use imaging for COVID-19 screening, but imaging
is performed in COVID-19 positive or suspected
patients, to rule out other diagnoses that can be
treated, including pulmonary embolism. In addition,
emergent imaging may be necessary for evaluation
of other urgent conditions, including stroke, trauma,
infection and other disease conditions.
Clinics and inpatient units are directed to call ahead
regarding COVID-19 positive or suspected cases so
that precautionary preparations to receive the patient

Figure 5 - Social distancing in Radiology Reading Room.

31

JUNE 2020

Figure 6 - Hand sanitizers and Alcohol wipes for Disinfection of
Workstation peripherals.
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With the aim to decrease foot traffic in radiology
reading rooms’ remote consultations by telephone
rather than in-person is encouraged.
Recurring departmental meetings and multiple
clinical conferences have been moved to video
conferencing. We are exploring strategies to allow
diagnostic radiologists to work from home and
developing guidance for when this is appropriate.
In addition to these measures, and taking in
consideration of the workload, the staff roster has
been changed to allow only the essential workforce
presence in the department.
In conclusion, the department’s response, policies and
protocols to this pandemic have been adapted up to
the maximum standards achievable.

COVID-19: An Alarm Bell for Healthcare
System in Pakistan!
Lessons to learn from COVID Pandemic to effectively cope with new, more severe
contagious diseases in future.
Dr Mohammad Zeeshan
Microbiology

Heraclitus, a Greek philosopher once said, ‘the
only constant in life is change’. And how so true
this statement is! We constantly discover, invent,
and improve to survive and grow in this world.
Interestingly, for those of us who don’t improve, life
creates situations and circumstances that force us to
bring in the much needed change.
The COVID-19 Pandemic is one such situation for
healthcare system in Pakistan. Today, the entire
healthcare industry from basic healthcare units
to multidisciplinary hospitals, has been given a
wake-up call. Medical personnel are grappling to
provide services and care to their communities, and
desperately putting their lives at stake to save patients.
The gaps and holes, inefficiencies and discriminations
in our system have been laid bare for all. Fixing this
falling system is a tall ask, and would require purity
of intent and persistence; however, few aspects need
to be address urgently.
32

Personnel and Institutional Safety
The concept of safety within our healthcare system
is almost non-existent and barring few exceptions, a
functional Hospital Safety Committee is an abstract
notion in most health facilities. Similarly, the
wellbeing of healthcare providers is a long neglected
case. The attitude of both the government and hospital
managements towards medical staff’s safety is
appallingly indifferent.
In recent COVID-19 scenario, the unprecedented
demand but interrupted, inadequate supplies of PPEs
(personnel protective equipment) has hit the panic
button for health care systems across the entire globe.
And in Pakistan, we are struggling even more. We
claim our healthcare staff to be frontline troopers, and
yet we fail to provide appropriate, ample safety gears
for them. The staff is exposed to health threatening
environment, putting their lives at jeopardy. This also
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has a ripple effect; these staff become source of spread
to other patients, attendants, colleagues, and even
their families.
Therefore, now is the right time for all small scale
healthcare centers and multidisciplinary institutes
to enforce a Hospital Safety Committee. For smaller
outfits, any senior doctor or head nurse with training
in infectious disease and an understanding of
safety regulations can be given the responsibility to
oversee affairs. For hospitals, a multi-disciplinary
committees should be formed that reports to the
facility CEO or Administrator. This committee must
preempt situations and liaise with health ministry
and provincial governments to ensure availability of
protective gears, testing and lifesaving equipment
and medicines through local and international
manufacturers. The committee should also ensure
safety regulations are being fully followed vis-àvis usage and disposal of gears and equipment, and
handling and disposal of corpses in case of infectious
epidemic.
Training of Healthcare Workforce
The entire healthcare workforce requires regular
upgrading of skills and rigorous training in new
approaches. This sadly is another neglected aspect
of our system. Despite being frontline defense, our
nurses and paramedics are not trained at grass root
level to handle expected panic situations such as
infectious disease outbreaks. Large medical facilities
are better off in coping with these situations through
mobilizing local resources and international health
agencies. However, BHUs and smaller medical
centers, which cater to the masses, struggle to serve.
The government should engage large hospitals to
assist in training these healthcare providers with
regular training (at cost) and secondments to keep
abreast. There can also be cascade training programs
where senior professional from each facility can be
trained as Master Trainers to disseminate learning to
others.
Data Sharing
During any ongoing outbreak, epidemic or largescale calamity, it is imperative to share reliable, real
time data with national and international public
health agencies. This helps in devising strategies to
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combat the situation, formulate or modify policies
and guideline, and avoid duplication of efforts
across. Therefore, our healthcare system must
have a uniform, structured, user friendly database,
compatible and integrated with other national and
global databases. There should also be clear SOPs for
sharing such data of reportable diseases with national
health agencies on regular basis.
Diagnostic Facilities
A rare, inspiring medical moment during this
COVID-19 Pandemic was Germany’s exemplary
effort of investing preemptively in laboratory
diagnosis, massive testing-kit production and
performing screening at mass level against
modern-day Frankenstein which lead to effectively
and proactively implemented policies for early
controls. The survival ratio of Germans is far more
encouraging contrary to the rest of Europe. For
Pakistan, it is a pressing need to develop capacity for
rapid procurement of reliable, authentic diagnostic
kits to perform testing with recommended validation.
Facilities with better infrastructure and workforce
situation must facilitate resource limited setting in
their capacity building.
Infection Prevention and Control Department
An active, efficient Infection Prevention and Control
Department is considered a linchpin in any healthcare
facility. The core responsibility of this team is to
ensure spread control of infections between patients,
healthcare personnel and visitors by breaking the
chain of transmission through introducing and
implementing stringent protocols and SOPs.
In our hospitals and clinics, the position of Infection
Preventionists is regrettably understated. This
professional has never been prioritized to be in the
list of essentials by healthcare managers. Therefore,
while reflecting on COVID-19 and conceiving
post pandemic strategies, the roles of Infection
Preventionists must considered critical and an
empowered infection prevention team must be put in
place.
n

Objectives and Responsibilities
The objectives and responsibilities of this
department must be clearly specified with a
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n

n
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strong underlying principle of well-being and
safety of workers, patients and visitors, and
ensuring a safe premises.
Standard Operation Procedures
The department must establish clear SOPs for the
Healthcare facility and workforce with additional
rules and regulations for any functional teams and
sub-committees.
Administrative Strategies
Implementation of SOPs has to be ensured
through a dedicated and professional ‘Safety
Officer’ and ‘Infection Control Practitioner’. In
case of resource limitation, a single Healthcare
professional be designated instead of a team. This
individual can work in close contact and under the
supervision of a senior doctor.
Risk Assessment
The infection prevention and control department
or individual is responsible for developing
a ‘risk assessment and mitigation framework’
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for the Healthcare facility and staff. Based on a
multidisciplinary approach, the framework should
define leveled scenarios from low risk to high and
state procedures for key aspects such as
modification in engineering systems, change
in hospital traffic flow, use of PPEs, proper waste
disposal, etc.
The COVID-19 Pandemic is a testing time for all.
There is sickness and death; and the visible future
is uncertain. The only hope in this maddening fear
is having a better Healthcare system that can fight
the pandemic and sustain till help arrives in from of
vaccine or other treatment. Therefore, we must latch
on the one opportunity this adversity offers – steer our
Healthcare system in the right direction. The gaps in
this system are most visible today. Let’s work together
– government, large hospitals and medical fraternity –
to bridge the gaps and build on!

Emergency Online Undergraduate Medial
Education During COVID 19
Dr Romana Idrees
Histopathology

The Covid 19 pandemic has adversely affected our
lives and the scales of its impact are unprecedented in
our life time. The deteriorating economic conditions
lock down, and safety issues of us and the family,
makes the situation quite stressful and uncertain. In
view of all this we faced a challenge of continuation
of educational activities for undergraduate medial
students so that they continue the learning activities
without risk of losing an academic year. We were
well aware of certain limitations specific for our
country such as lack of internet access in remote
areas of the country, laptops accessibility, and trained
technology savvy man power.
Detailed plans were devised for delivering content,
attendance record, assessments, number of sessions
per day and faculty student adaptability for the online
platform. As most of the faculty was comfortable with
delivering face to face sessions and had never used
34

an online platform for teaching learning purpose, this
was and added challenge. Beside this students were
also thinking it as boring and far-fetched.
After exploration and thorough discussion with the
IT team, we decided to use Microsoft teams as an
online portal that best fit for conducting our classes.
Following this, we planned a series of scheduled
training sessions for faculty and administrative staff
where they received orientation on how to operate
MS team. Finally we conducted an orientation session
with the students to inform them regarding the newly
established online system for learning. Students
were guided on how to use MS team. In addition,
we developed video tutorials and easy to follow flow
charts to be shared with all faculty members, detailing
the basics of platform and delivering online sessions.
To address any issues, separate admin support
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WhatsApp groups were developed for faculty and
students. These served as command and response
centers during the online sessions. Minor hiccups
like disruptions of internet connection or login issues
for the students were faced in the first orientation
session. However, these issues were resolved in real
time. With the commencement of online teaching we
were able to complete all the essential component of
the module in the form of LCF,PBL and tutorials. Few
Labs were also converted into LCF.The clinical skill
sessions, sign off labs and few embryology lectures
will be done one students join back the campus.
Despite some challenges, we noted few advantages
of this emergency shift. Faculty members who were
earlier reluctant to deliver content online or to prerecord their lectures; were happily recording the
lecture sessions and/ or converting them as Flipped
classes. This resulted in providing students an
opportunity to learn as per their convenience as they
can review the lecture anytime. We have received
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encouraging and positive students’ feedback as their
classes schedule is almost the same keeping them
busy. We conducted online mid module and end of the
module formative exams comprising of 20-30 MCQs
and two SAQs.The passing percentage was 70 percent.
All students took the exam and found it useful in
enhancing learning.
In addition there was an increase in student
attendance and engagement. During the online
lectures, students put forth numerous logical
questions on the session chat which were addressed
by the teachers. Therefore, the fear of lack of connects
or student interaction was rebutted.
During this whole exercise we acknowledged the core
values of teamwork, support from the leadership,
and consistent effort by the faculty along with the
eagerness to learn displayed by our very academically
gifted students. These were the major driving forces
which made this learning experience a great success.

Challenges and Success Factors of Going
Online with the Endocrine and Reproduction
Module in Undergraduate Medical Education
at Aga Khan University
Dr Lena Jafri
Clinical Chemistry

Online teaching takes a lot of preparation! Once
COVID 19 hit Pakistan, as Chair of Endocrine
and Reproduction Module in Undergraduate
Medical Education (UGME) at Aga Khan
University, I was informed to shift the module
to an online format just few weeks away from
commencement of the module. Like everyone
else we were also not prepared for COVID 19,
however in order to continuity in teachinglearning a plan was devised. We knew we will be
facing hiccups as we had to work with tools we
were not familiar with.

Challenges Faced
l
l
l
l
l
l

l

Rush to get teaching moved to an online format.
Poor connectivity was faced by few students and
faculty at times during online sessions.
The myriad complexities involved in moving a
face-to-face course into the online format.
Training of faculty to teach online.
Students Assessments.
Conducting ‘Flipped Class Room’ in an online
format. With students feedback we tried to make
it case based or with quiz and guided faculty to
refrain from didactic online lectures.
How to teach clinical and communication skills?
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Success Factors
l
l
l
l
l

l

l

l
l

l
l
l
l
l
l

Planning in no time! Find time to plan.
Creating a Game plan with clear final outcomes.
Creating a project timeline.
Clarify for your team the specific set of 		
expectations and responsibilities associated with
their roles.
Recognize and encourage positive energizers in
your organization who have interest in your
module/ teaching and involve them.
Experience of Year 2 UGME team. Gave the
provision of online training to faculty on how to
conduct online lectures and PBLs.
Available assistance from Office of UGME, Aga
Khan University
Available assistance and experience of institute’s
IT and Academics and Blended and Digital
Learning Network.
Tech savvy students.
Energized faculty ready to adapt to change.
Faculty and staff adapted to cope with the
situation.
Focus on the positive and reframe obstacles into
positive challenges.
Identify strengths of your team members, and use
to the benefit of the team.
Two years’ experience of running our module
in blended format with handful of faculty and

l

l
l

staff trained on virtual learning environment.
We had Moodle Champs within our Department
that we had trained in the past and were engaged.
Express appreciation to students, faculty and
staff (e.g., making appreciative comments, emails
and notes a daily practice).
Staying connected with your module team
members, with students, with faculty and staff.
Due to COVID 19 Pandemic, change was easy!

Recommendations
All involved in teaching should be prepared to teach
online once in a while because after this pandemic
is over who knows when a similar situation like this
may arise again. Sometimes even in harsh weather
issues like heavy rainfall in Karachi it might be wise
and more desirable for students and faculty to stay
home and teach from a distance. It may be wise for
educational institutes to encourage faculty to spend
some of their time teaching online to gain experience
and prepare themselves. As online teaching and
learning continues to grow, a growing number of
faculty will be requested or even required to develop
curricula and teaching in this environment. Beyond
the pandemic can online teaching learning ever be
as effective as the face to face traditional teaching
methodology and is teaching-learning online here to
stay?

Adopting Virtual Teaching During the PandemicAn Overview of the Utility of ‘Microsoft Teams’
from an Educator’s Perspective
Dr Sibtain Ahmed
Clinical Chemistry

Owing to the leading health crisis of the COVID-19
pandemic, most educational institutes including
medical universities worldwide have shut their
campuses to mitigate the spread. In response,
teaching is being transformed from physical
class rooms to online, on an unprecedented
scale; certainly, with a hand full of trial and
error and experience building for the educators,
students, curriculum developers and institutional
36

administration.
Why ‘Microsoft Teams’, for Online Teaching?
Though there are numerous online platforms
available for virtual learning, Microsoft Teams
offers a suite of communication tools that are user
friendly and more importantly easily accessible
alongside the company’s Office 365 subscription for
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windows at no additional charges. The application
(app) can be accessed from windows, iOS and
Android based platforms ranging from PCs to
handheld devices with internet connectivity on the
go.
How to Learn, to Use ‘Microsoft Teams’?
To begin with, it is advisable to skim through the
variety of tutorials, freely available on YouTube
and Microsoft 365 online help, although mastering
the utility of the app comes with hands-on real-time
practice, preferably with a small group initially.
What are the Features of the App in a Nutshell?
Class rooms which the app defines as ‘TEAMS’
can be constructed based on specific criteria. The
occupancy of the team can range from the entire
batch for instance for a lecture or a small group of
students for problem-based learning with facilitator.
A video chat with up to 250 people at once or a
live presentation with up to 10,000 people can be
held via the app. A specific URL or invitation is
sent by a team owner, allowing the participants to
connect. Certain topics for discussion can be set
up within the teams by the teacher which the app
terms as ‘Channels’. Pupil can reply via text as
well as images, GIFs. Educators can also use direct
messages to pursue individual feedbacks.
Real time online classroom can be scheduled or
created ad-hoc which the app terms as ‘Meetings’.
The participants are able to see that a meeting is
currently in progress and the facilitators have the
option of sharing their screens. Additionally, the
app also offers a plugin for Microsoft Outlook to
invite others into a Teams meeting. This feature
proves to be handy in cases you want a guest
lecturer or invited facilitators to join.
How to Plan a Flipped Classroom with the App?
For the Flip classrooms, the pre reading material,
videos, animations etc. can be circulated within
the team using the app. This option is especially
helpful for those institutes which do not have
prior virtual learning environment in place like
MOODLE.
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Is there any option for Assessment?
As far as assessment is concerned, the app has
a ‘Assignments tab’ which allows teachers to
distribute, provide feedback, and grade student
assignments. Pre and Post Test activities for e.g. a
quiz can also be assigned to students through an
integration with Office Forms.
Is there option for Recording and online Cloudbased Storage?
Another substantial benefit is ease of recording
lectures and presentations and sharing with the
team. Also comes built in is shared storage in
SharePoint Online and participants get personal
storage in OneDrive, consisting of 2GB for a free
account and 1TB for a fully licensed Office 365
account. This resource pack can be utilized by the
students as well as the teachers from anywhere,
with merely a phone and internet connectivity for
future reference and learning without carrying
heaps of books and notes.
Does it offer Connectivity with other Apps used
by the Institution?
Moreover, if there are other tools that your
institutions have already standardized on like
ZOOM; Microsoft Teams has an option via “Apps’
to connect those apps directly and then switch to
that platform as per the requirement.
What are the noteworthy advantages of this
virtual teaching platform?
Furthermore, other numerous advantages include
cost saving in terms of overhead cost for setting
up and attending physical classrooms both for the
institution as well as the students. Space constraints
specially pre-booking of rooms for classes has been
overcome by the virtual podium. Disruption of
educational activities owing to various unfavorable
circumstances like natural calamities and low and
order situations in certain locations can no-longer
become a hindrance for teaching and learning
activities. With this user-friendly app even for the
novice users, no hardcore and time-consuming
trainings are required.
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Any distinct advantage for Postgraduates?
From a medical educator’s standpoint, the
undergrad medical students have dedicated and
scheduled learning activities, on the contrary
postgraduate trainees owing to their workplace
duties suffer from time constraints and are often
unable to attend physical class rooms. This is
where, this app can do wonders, allowing ease of
learning, live as well as remotely for the trainees as
well as the ‘busy clinical faculty’.
Are there any Limitations?
On the other side of the picture, there are certain
limitations associated with this mode of learning.
The lead is lack of adaptivity, fluctuating comfort
levels and engagement of students with their online
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instructors or their virtual classmates. Disruption
in internet services is also a issue in certain
areas often restricting the use of technology for
certain users.
Way Forward
From a broader perception, changing the mode
of delivery of education, is not just a switch from
one app to another, rather it’s about changing
behavior and habits of the learners and the
facilitators, that have been ingrained over
decades. Building effective online classrooms,
will require self-discipline on both ends, time,
experience and commitment. However, the present
world situation has given us all the reasons to move
online and reform our educational system for better
productivity.

Reframing rare in Pakistan: An Experience
of Conducting a Successful Multidisciplinary
Conference in the face of COVID-19 Uncertainty
Dr Hafsa Majid
Clinical Chemistry.
A Multidisciplinary Conference on ‘Newborn
Screening for Rare Disorders in Pakistan’ was
held from March 4th to 7th 2020 at the Aga Khan
University (AKU), Karachi, Pakistan. Conference
was arranged by Department of Pathology and
Laboratory Medicine and the Division of Women
and Child Health, AKU in collaboration with
Departments of Biological & biomedical Sciences
and Obstetrics and Gynecology, AKU and national
societies including Pakistan Society of Chemical
Pathologists, Pakistan Medical Association,
Pakistan Pediatric Association, Pakistan Society
of Hematology and Pak IMD-Net. Rare diseases
affects many aspects of an individual’s life
including their social, educational and employment
opportunities and is an emerging global public
health priority. When consider together, “rare”
diseases are not so rare after all. According to
38

an estimate around 300 million people, i.e. four
percent of the world’s population suffers from
these conditions. Therefore public health policies
at global and national level are needed to address
this issue. Such a policy is becoming reality
in many countries around the globe. However,
non-availability of diagnostic facilities, delayed
diagnosis, misdiagnosis, difficulty accessing
appropriate information, difficulty accessing care,
availability of experts help and poorly coordinated
care are still the norm for rare disease patients and
their families in Pakistan.
In this scenario, it is important for us as a nation
to think that how can we form collaborations
to facilitate resource development. Health care
providers, and experts from the different institutes
of the country participated in it. The primary
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Picture 1: Picture of Conference Organizers and Speakers.

aim was to break the silos and bringing synergies
between healthcare personnel’s working in the
field of rare diseases in Pakistan, building bridges
between then, bringing them on one platform
where they can come together, understand the
issues of rare diseases and come up with concrete
steps that can be implemented within tight
timeframes after the conference. On February
1st, the programme looked fine with some 21 oral
presentations, 70 posters, four pre-conference
workshops, four international guests and nearly
15 national experts coming from different cities
of Pakistan. We also planned four pre-conference
workshops including ‘Establishing Registries for
Tracking Patient Outcomes’, ‘Genetic Counseling:
How to do it right?’, ‘Bioinformatics hands-on on
IMD genomics’ and ‘Essentials of establishing a
newborn screening program’. Things were looking
good. Then Corona hit furiously. In Pakistan the
first corona patients were reported on February
26th, 2020, before the meeting even began. We
were all on tenterhooks, whether our participants

and speakers, especially international speakers
will be able to come because of travel restrictions.
We kept in close contact with them, made backup plans in case they were not able to come. Our
administrative team played an important role in it
they made sure that all the participants/speakers
face no hiccups in registrations. Fortunately,
the most if not all of all of the International
and National speakers were able to attend the
conference. And very good discussions were
generated in all the workshops and conference
talks, participants were enthusiastic. The workshop
participants were from all over Pakistan, and
overwhelmingly engaged into talks, and interactive
hands-on learning activities. The participants gave
a good evaluation for each workshop both formally
and informally indicating that these activities
helped them brainstorm ideas of common interest.
It was a huge learning experience for us in terms
of conducting a conference in these times of
uncertainty and many of the lessons we learned can
be applied to future conferences.
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The Best of the Recent Past
#COVID19 # #Pathologists #Followtheirlead #changeagents
Interview of the Chair of Pathology and Laboratory Medicine, Professor Afia Zafar
Recorded by Dr Lena Jafri

1. As we navigate through the uncertain times of
‘COVID19’ do you feel the same level of motivation
every morning while coming to AKU?
Professor Afia: Since the beginning of the lockdown
in Karachi in March I have been coming to AKU
everyday with the same zeal and commitment. I feel
responsible and I am happy to serve my department,
my institute and my community. As an infection
control expert, I have also been occupied and engaged
in various activities related to Covid-19 within the
institute.
2. What challenges are you facing in a time like
this and what were the success factors that helped
you respond to these challenges?
Professor Afia: These are challenging times
and we expect our staff to work in such difficult
circumstances. For me trying to provide safe
environment for all was one of the major concerns.
The leadership my peers and colleagues have
remained connected, supportive and helped me find
solutions to any kind of problem during these times.
Despite, the financial constraints, and uncertain
future both in terms of the disease and their own
future everyone in my department is still contributing
for the love of humanity. Everyone at every level has
been supportive and has been working for humanity
and I really appreciate it.
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3. Was there any
‘AHA moment’ at
workplace during
these difficult COVID
times?
Professor Afia: The
AHA moment for
me was when we
started the diagnostic
testing for COVID-19
patients. With this
service we were the first ones to serve the community.
Another big moment was the ‘Fit Test Service’ by
my department through which till to date more than
thousand personnel have been trained which was all
possible with mutual teamwork.
4. Any advice to prestige readers on how to stay
positive in this dire time?
Professor Afia: Stay connected with junior staff and
keep supporting each other. Do not limit your efforts
to your section, department or hospital in short have
a holistic approach. We as medical practitioners are
trained to cope with challenges and to serve mankind
in any circumstances. Our seniors in this profession
have set the bar high for us to follow and we will
continue to endeavor.
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The Best of the Recent Past
#COVID19 # #Pathologists #Followtheirlead #changeagents
Interview of the Professor of Pathology and Laboratory Medicine,
Professor Zahra Hasan
Recorded by Dr Najia Ghanchi
1. How is the typical day at work now different
from the one before the COVID-19 outbreak?
Professor Zahra: For the past two months the work
days have been long and engaging – it’s a marathon
rather than a sprint. There is an urgency in the
laboratory to work through the COVID-19 testing
at different levels. It took us some time to set up
workflows that could be easily followed as the teams
have grown. The operations of testing are running
smoothly with the cooperation of all sectional faculty
and technical staff who have been fantastic. Further,
we are constantly trying to bring in new innovations
into the testing, pooling of PCR samples in batches,
validating new kits, trying out alternate specimens,
each day brings new queries and due to the nature of
the disease there is an urgency to deal with things as
rapidly as possible.
2. What challenges did you face in establishing
and leading COVID-19 testing at AKUH clinical
lab and what were the success factors that helped
you respond to these challenges?
Professor Zahra: The first challenge was
procurement of necessary reagents when we decided
to go ahead and establish a laboratory developed
test (LDT) when we saw the virus spreading in
and outside of Wuhan, China in January 2020.
Waiting three weeks for reagents seemed like
eternity. However, the reagents did come in and
with the help our fantastic faculty and staff team
at Molecular Pathology we were able to set up the
assay. Dr. Kiran Iqbal and Dr. Najia Ghanchi have
been relentlessly working on improving the testing
methods and have done validations and verifications
of many commercial assays for SARS-CoV-2 as
we now run CE-IVD marked assays. The whole
team is involved in this effort. Dr. Zeeshan, Section

Head has facilitated all
the necessary ordering,
all of us have a rapid
reporting rota. Nazneen
Islam, the lab manager
has done a fantastic job of
coordinating staff rotas,
training, coordination
with purchase. A special
thanks to Sohail Baloch
for keeping up with all of
our demands. Due to the
biosafety requirements of working with SARS-Cov-2
testing collaboration with Section of Microbiology,
Dr Rumina and Dr. Erum who have helped use the
Biosafety Level 3 laboratory as effectively as possible.
The lab management has been very supportive and
it has been a multi-dimensional and multi-sectional
effort to keep up the requirements for COVID 19
testing.
3. How do you feel when you see your laboratory
team work tirelessly day and night responding to
patients need in this time of crisis?
Professor Zahra: I feel very proud that we have been
able to sustain the workflow, work ethics and do our
best each day in this demanding time. I do worry
about keeping them safe and feel that the PPE needs
to be taken care of at all time.
4. How rewarding it is to be working behind
the scenes and to tackle this pandemic headon supporting patient who are battling with
COVID-19?
Professor Zahra: I believe we are already seeing the
impact that we at AKUH have had on diagnostics of
COVID-19 testing at the institutional, provincial and
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national levels. We are involved in guidance to other
institutions for SARS-CoV-2 testing. Initially for RTPCR and now regarding the serology based assays as
well. The innovations and improvements we bring in
can benefit a maximum number of people when we
work cooperatively.
5. Times of crisis have historically also been
opportunities for change. Are you optimistic that
as we emerge from this, it could be a chance to be a
health care facility a lot more equipped to face the
challenges like this better than before?
Professor Zahra: Yes, indeed. The Clinical
Laboratory management, Hospital management and
the Dean have all been involved in making this a
concerted and rapid effort. We have learned a lot
the past two months and hope that it will leave us
in a better place to work quickly if faced with other
challenges.
6. As per daily updates, the incidence of
COVID-19 is on rise. How is your team responding
to meet the needs of huge number of patients
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coming in requiring rapid testing?
Professor Zahra: We are staying on track with our
plans for testing through the day with regular cutoffs. We have involved additional staff from other
sections to organize the set-up of testing. It has helped
to streamline the organization of samples, preparation
of batches and set up of large batches for the highthroughput testing by sending people to BSL3 in
pairs. We have learned that as long as every step of
the process is organized properly it is possible to scale
up effectively.
7. Do you see a process map in near future
that will support the extensive patient testing
throughout the country?
Professor Zahra: I believe we have the organization
capacity to support expanded testing throughout
the country provided that bottlenecks such as space
for sample organization, storage and additional
equipment can be provided. We have an opportunity
to impact COVID-19 diagnostics throughout Pakistan

The Best of the Recent Past
#COVID19 # #Pathologists #Followtheirlead #changeagents
Interview of the Chief Resident of Pathology and Laboratory Medicine,
Dr Ruhul Quddus
Recorded by Dr Anila Rashid
1. As we navigate through the uncertain times of
‘COVID19’ do you feel the same level of motivation
every morning while coming to AKU?
Dr. Ruhul Quddus: Yes, I do feel the same level
of motivation each day. Although in the start there
were uncertainties but just like any other medical
professional I relied on my clinical instincts regarding
the situation and continued to practice the preventive
and precautionary standard practices accordingly
2. What challenges are you facing in a time like
this and what were the success factors that helped
42

you respond to these
challenges?
Dr. Ruhul Quddus:
The challenges that I
personally and in general
most of us faced in the
start were: the risk of
exposure to or contracting
the COVID. Also, I had
to come up with a plan
in order to manage the
situation, according to the hospital guidelines, i.e.
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reducing the exposure without compromising the
work and patient care. Additionally, to look after,
to morally support and to counsel my colleagues/
residents/medical officers that were on frontline or
those who went to isolation or quarantine were at
times overwhelming.
As in every case, it wasn’t a one-man effort at all.
We achieved success through coordinated teamwork
which in part was also contributed by the ability of
everyone to listen to us and to understand us. The
other half of success, obviously, is everyone staying
positive dissociating all negative news/information,
and sticking to the standard precautions and
preventive measures.
3. Was there any ‘AHA moment’ at workplace
during these difficult COVID times?
Dr. Ruhul Quddus: One of the big moment for me,
despite all the negativity, was seeing the commitment
of faculty, residents, medical officers who continued
their duties and the facilitation by others staff. Some of
our colleagues actually going on the frontline was a real
inspiration. While others volunteered for and conducted
awareness sessions and facilitated training sessions.
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4. Any advice to prestige readers on how to stay
positive in this dire time?
Dr. Ruhul Quddus: Always stay positive and be
hopeful. Avoid anxiety-provoking news and articles
on social media. Do something that brings you joy and
which keeps your time and mind occupied. You can
utilize your time to study, read or complete your other
unfinished work and researches. Share your anxiety
and fears with those colleagues who can give you
positive and optimal response.
5. As an expert what changes do you propose
to the institute to gear up for another such
eventuality in the future?
Dr. Ruhul Quddus: In any emergent or disastrous
situation, time is of the critical essence. There should
be contingency plan in place all the times which can
be used should the situation or need arise. It will help
us saving the time and utilizing this time directly on the
implementation of the plan. We should also have backup
plans in case if we cannot cope with the situation or if the
primary contingency plan fails. In order to contribute to
general public, we should also have good social media
coverage in order to reach to them. It will also help us to
conduct public awareness sessions.

The Best of the Recent Past
#COVID19 # #Pathologists #Followtheirlead #changeagents
Interview of the Medical Officer of Pathology and Laboratory Medicine,
Dr Aniqa Arshad Raza
Recorded by Dr Siraj Muneer
1. As we navigate through the uncertain times
of ‘COVID19’ do you feel the same level of motivation
every morning while coming to AKU?
Dr Aniqa: Yes, it’s true that the prevailing situation
due to spread of COVID-19 is unprecedented yet
realizing the hopefulness and trust of the patients on
us to keep our doors open even during times of
pandemic, makes me feel motivated. I believe the
AKU plays an important role in keeping us motivated
as well, everyone here follows the safe practice

recommendations, we are
provided with appropriate PPEs
and the trust that here at AKU
staff safety comes first and
foremost. I feel blessed to be
working at AKU and be able to
serve the humanity through this
noble profession.
2. What challenges are you facing in a time like
this and what were the success factors that helped
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4. Any advice to our prestigious readers on how
to stay positive in this dire time?

you respond to these challenges?
Dr Aniqa Raza: Direct interaction with the patients
who are suffering from this lethal virus can expose
even the doctors to critical hazards, especially
patients who are asymptomatic. However our
repeated trainings have ingrained in us to follow
the safe practice guidelines and use appropriate
PPEs. With the support of our head, chief resident
and cooperation of my colleagues we were able to
respond to all challenges with the determination to be
successful in this turbulent time.

Dr Aniqa: I would like to encourage my counterparts
to keep serving the humanity indefatigably for the
triumph of health over disease. To all those heroes I
dedicate this quote, “Not all angels have wings some
have stethoscopes”. They are truly angels. For the
public I would advise to STAY HOME STAY SAFE
unless it’s extremely important to go out. In that case
don’t forget to adopt all the precautionary measures.

3. Was there any ‘AHA moment’ at workplace
during these difficult COVID times?

5. As an expert what changes do you propose to
the institute to gear up for another such eventuality
in the future?

Dr Aniqa: Yes, I’m amazed at the team spirit with
which we are all enthusiastically working together to
achieve a common goal of countering COVID-19 and
I’m proud of being an active member. It was also an
‘AHA moment’ for me to be chosen to provide training
of propharangeal swabs and nasopharangaeal swabs
techniques to fellow doctors and technical staff to
defeat this pandemic. Also safe COVID-19 testing zone
for sampling of patients for screening Corona was an
experience that amplified my own expertise and further
enhanced my understanding about the pandemic.

Dr Aniqa: A pandemic situation demands a rapid
response and huge capacity building. To treat and
accommodate maximum number of patients while all
departments of the hospital should remain operational
too is a mammoth task. Training of the paramedics
should be multiplied further to respond to any
emergency situation in a better way. The proper gear
and equipment should be in functional position and in
sufficient quantity to deal unforeseen circumstances
of high magnitude.

Polaroid

Picture 1: Some of the Histopathologists reporting during COVID 19 pandemic days
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Polaroid

Picture 2: CME Webinar “Covid-19 Imaging, An Essential Tool to Diagnose & Treat” held on 19th April, 2020
Presentations, Course design and Moderation by AKU Radiology faculty (Dr Nadeem Ahmad, Dr. Kiran Hilal and
Dr Muhammad Azeemuddin

Picture 3: Staff at the Section of Chemical Pathology has been working day and night to deliver accurate and timely
reports. Picture shown is of COVID-19 warriors from the Section of Chemical Pathology taken in April 2020.
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Picture 4: Multiple COVID-19 Awareness and training sessions were conducted for the staff at the Section of Chemical
Pathology. Picture shown is of one such awareness session conducted on 27th February 2020 at the Section of Chemical
Pathology.

Picture 5: Health care team, Ultrasound Suite-Department of Radiology during COVID times.
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Picture 6, 7 & 8: N95 Fit testing performed by microbiology faculty and residents for health care workers of Aga Khan Hospital
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Picture 9: Meet the Molecular Pathology Faculty who developed the COVID-19 test at Aga Khan University. Reporting
first case of SARS-CoV2 from Pakistan.

Picture 10: COVID 19 warriors at section of molecular pathology, AKUH clinical laboratories working day and night
performing complex critical testing and delivering quality results on time
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Picture 11: COVID warriors working in Biosaftey level 3 (BSL-3) laboratory taking appropriate precautionary measures
performing SARS CoV 2 testing according to international standards.
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Picture 12 & 13: In service teaching and training session for health care workers regarding Infection prevention in health care
setting during COVID 19 pandemic at Abbasi Shaheed hospital by Microbiology faculty and resident

Picture 14: COVID-19 Sample Collection Booth at Aga Khan University Karachi. These single modular booths provide a
physical barrier separating patients and the healthcare staff.
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Picture 15: Dr Bushra Moiz delivered talk on Inherited thrombophilia testing in a CME “Reframe Rare in Pakistan”,
held at AKU in March 2020

Picture 16: COVINAR, special course series with over 3500 registrations, organized jointly by DCPE and DED.
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THE AGA KHAN UNIVERSITY HOSPITAL
CLINICAL LABORATORIES
UPDATE
Detection of Novel Coronavirus-2019 (COVID-19)
by Real Time PCR
VOL. XXVI No. 3, 2020
Introduction
Coronaviruses, named for the crown-like spikes on their surface. Around the world, most common
mild to moderate respiratory coronavirus infections in humans are by 229E, NL63, OC43, and
HKU1. Sometimes coronaviruses that infect animals (zoonotic viruses) can evolve and transmit to
humans and become a new human strain. Two zoonotic coronaviruses, SARS-CoV (2002-2003)
and MERS-CoV (since 2015), are known to cause severe illness in humans. A recent example of
such emergence from Wuhan, China is the novel coronavirus, COVID-19.
Person-to-person spread of COVID-19 is via respiratory droplets produced when an infected
person coughs or sneezes. The incubation period is 2-14 days. Symptoms include fever, cough
and shortness of breath; suspicion increases when patient has history of travel to affected areas
(especially China and other Far Eastern countries) in the last 2 weeks. Suspected cases with
respiratory infection and recent travel to affected countries should be tested for COVID-19. All
such patients who need hospitalization for management, should be tested at the earliest and
contact isolation precautions instituted till COVID-19 infection has been ruled out.
Principle of the Assay:
Real-time (RT- PCR) assays for the in vitro qualitative detection of Novel Coronavirus-2019
(COVID-19) is used. Results interpretation is based on detection of fluorescent signals.
Specimen Collection:
Note: For initial diagnostics testing of COVID 19, Centers for Disease control and
Prevention(CDC) and World Health Organization(WHO) recommend to collect nasopharynx and
oropharynx swab in a same tube to increase the viral load.
Use only synthetic fiber swabs with plastic shafts. Do not use calcium alginate swabs or swabs
with wooden shafts as they may inhibit PCR testing or inactivate some viruses.
Collecting the Oropharynx swab.
Insert swab into the posterior pharynx and tonsillar areas. Rub swab over both tonsillar pillars and
posterior oropharynx and avoid touching the tongue, teeth, and gums.
Collecting the Nasopharyngeal swab.
Insert swab through the nares parallel to the palate (not upwards) until resistance is encountered
or the distance is equivalent to that from the ear to the nostril of the patient indicating contact with
the nasopharynx. Gently, rub and roll the swab. Leave the swab in place for several seconds to
absorb secretions before removing.
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Sputum
Educate the patient about the difference between sputum and oral secretions. Have the patient
rinse the mouth with water and then expectorate deep cough sputum directly into a sterile screwcap collection cup or sterile dry container
Upper respiratory specimens including nasopharyngeal or oropharyngeal swabs in a special tube
containing Universal Transport Medium (available from the clinical laboratory)
Lower respiratory specimens including Broncho-alveolar Lavage (BAL), tracheal aspirates and
sputum in sterile container.
Reporting Schedule:
COVID-19 virus RT-PCR is performed and reported daily if specimen is received before cut off

11:00 am (excluding Sunday)

54

JUNE 2020

VOL 46, ISSUE 2

55

hospitals.aku.edu/Karachi/clinical-laboratories

56

